PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  1  
  
 
Title  Page  
 
 
A PHASE  1, OPEN -LABEL,  SINGLE -DOSE,  PARALLEL  GROUP  STUDY  TO 
COMPARE THE PHARMACOKINETICS OF PF -07081532 IN ADULT 
PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT 
RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT  
 
 
Study  Intervention  Number:  PF-07081532  
Study  Intervention  Name:  NA 
US IND Number:  CCI  
EudraCT/CTIS  Number:  NA 
ClinicalTrials.gov ID: Not available  
Pediatric  Investigational  Plan  Number:  NA 
Protocol  Number:  C3991009  
Phase:  1 
Brief  Title:  A Study  to Investigate  the Effects  of Hepatic  Impairment  on the 
Pharmacokinetics of PF -07081532  
 
 
 
This document  and accompanying  materials  contain  confidential  information  belonging  to Pfizer.  Except  as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this 
information  in confidence  and not copy  or disclose  it to others  (except  where  required  by applicable  law) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.  

PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  2  
 Document  History  
 
Document  Version  Date  
Original  protocol  18 May  2022  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  3  
 TABLE  OF CONTENTS  
LIST  OF TABLES  ................................ ................................ ................................ ....................  8 
1. PROTOCOL  SUMMARY  ................................ ................................ ................................ .... 9 
1.1. Synopsis  ................................ ................................ ................................ ....................  9 
1.2. Schema ................................ ................................ ................................ ....................  16 
1.3. Schedule  of Activities  ................................ ................................ .............................  16 
2. INTRODUCTION  ................................ ................................ ................................ ...............  19 
2.1. Study  Rationale  ................................ ................................ ................................ ....... 19 
2.2. Background  ................................ ................................ ................................ .............  19 
2.2.1.  Nonclinical Pharmacology  ................................ ................................ .........  19 
2.2.2.  Nonclinical  Pharmacokinetics  and Metabolism  ................................ .........  19 
2.2.3.  Nonclinical  Safety  ................................ ................................ ......................  20 
2.2.4.  Clinical  Overview  ................................ ................................ ......................  20 
2.2.4.1.  Clinical Safety  ................................ ................................ ..........  21 
2.2.4.2.  Clinical Pharmacokinetics  ................................ ........................  21 
2.3. Benefit/Risk Assessment  ................................ ................................ ........................  23 
2.3.1.  Risk Assessment  ................................ ................................ ........................  23 
2.3.2.  Benefit Assessment  ................................ ................................ ....................  25 
2.3.3.  Overall Benefit/Risk Conclusion  ................................ ...............................  25 
3. OBJECTIVES  AND  ENDPOINTS  ................................ ................................ ....................  25 
4. STUDY  DESIGN  ................................ ................................ ................................ ................  26 
4.1. Overall  Design  ................................ ................................ ................................ ........  26 
4.2. Scientific Rationale for Study  Design  ................................ ................................ .... 27 
4.2.1.  Choice  of Contraception/Barrier  Requirements  ................................ .........  29 
4.2.2.  Collection  of Retained  Research  Samples  ................................ ..................  29 
4.3. Justification for Dose  ................................ ................................ ..............................  30 
4.4. End of Study  Definition  ................................ ................................ ..........................  30 
5. STUDY POPULATION  ................................ ................................ ................................ ..... 30 
5.1. Inclusion  Criteria  ................................ ................................ ................................ .... 31 
5.1.1.  Participants  in All Groups  ................................ ................................ ..........  31 
5.1.2.  Additional Inclusion Criteria for Group 1 Only (without Hepatic  
Impairment)  ................................ ................................ ................................ ..... 31 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  4  
 5.1.3.  Additional Inclusion Criteria for Groups 2, 3 & 4 Only (Hepatic  
Impairment)  ................................ ................................ ................................ ..... 32 
5.2. Exclusion Criteria  ................................ ................................ ................................ ... 32 
5.2.1.  Participants  in All Groups  ................................ ................................ ..........  32 
5.2.2.  Additional Exclusion Criteria for Group 1 Only (without Hepatic  
Impairment)  ................................ ................................ ................................ ..... 34 
5.2.3.  Additional Exclusion Criteria for Groups 2, 3 & 4 Only (Hepatic  
Impairment)  ................................ ................................ ................................ ..... 35 
5.3. Lifestyle  Considerations  ................................ ................................ .........................  36 
5.3.1.  Contraception  ................................ ................................ .............................  36 
5.3.2.  Meals and Dietary  Restrictions  ................................ ................................ .. 37 
5.3.3.  Caffeine,  Alcohol,  and Tobacco  ................................ ................................ . 38 
5.3.4.  Activity  ................................ ................................ ................................ ...... 38 
5.4. Screen  Failures  ................................ ................................ ................................ ........  38 
6. STUDY  INTERVENTION(S)  AND  CONCOMITANT  THERAPY  ................................ . 39 
6.1. Study  Intervention(s)  Administered  ................................ ................................ ........  39 
6.1.1.  Administration  ................................ ................................ ............................  40 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ..............  40 
6.2.1.  Preparation  and Dispensing  ................................ ................................ ........  41 
6.3. Assignment to Study Intervention  ................................ ................................ ..........  42 
6.4. Blinding  ................................ ................................ ................................ ..................  42 
6.4.1.  Blinding  of Participants  ................................ ................................ ..............  42 
6.4.2.  Blinding  of Site Personnel  ................................ ................................ ..........  42 
6.4.3.  Blinding of the Sponsor  ................................ ................................ .............  42 
6.5. Study  Intervention  Compliance  ................................ ................................ ..............  42 
6.6. Dose  Modification  ................................ ................................ ................................ .. 42 
6.7. Continued  Access to  Study  Intervention After  the End  of the Study  .....................  43 
6.8. Treatment of Overdose  ................................ ................................ ...........................  43 
6.9. Prior  and Concomitant  Therapy  ................................ ................................ ..............  43 
6.9.1.  Participants  in Group  1 Only  (without  Hepatic  Impairment)  .....................  44 
6.9.2.  Participants  in Groups  2, 3 & 4 Only  (Hepatic  Impairment) .....................  44 
6.9.3.  Rescue  Medicine  ................................ ................................ ........................  44 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  5  
 7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT  
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ...........  45 
7.1. Discontinuation of Study  Intervention  ................................ ................................ .... 45 
7.2. Participant Discontinuation/Withdrawal From the Study  ................................ ...... 45 
7.2.1.  Withdrawal  of Consent  ................................ ................................ ..............  45 
7.3. Lost to Follow -up ................................ ................................ ................................ ... 46 
8. STUDY  ASSESSMENTS  AND  PROCEDURES  ................................ ..............................  46 
8.1. Administrative  Procedures  ................................ ................................ ......................  46 
8.2. Efficacy  Assessments  ................................ ................................ .............................  47 
8.3. Safety Assessments  ................................ ................................ ................................ . 47 
8.3.1.  Physical  Examinations  ................................ ................................ ...............  47 
8.3.2.  Vital  Signs  ................................ ................................ ................................ .. 48 
8.3.2.1.  Blood Pressure and Pulse Rate ................................ .................  48 
8.3.3.  Electrocardiograms  ................................ ................................ .....................  49 
8.3.4.  Clinical  Safety  Laboratory  Assessments  ................................ ....................  49 
8.3.5.  Management of Hypoglycemia  ................................ ................................ .. 50 
8.3.5.1.  Definition  and Severity  of Hypoglycemic  Adverse  Event  
(HAE)  ................................ ................................ ...............................  50 
8.3.6.  COVID -19 Specific  Assessments  ................................ ..............................  52 
8.3.7.  Pregnancy  Testing  ................................ ................................ ......................  52 
8.4. Adverse  Events,  Serious  Adverse  Events,  and Other  Safety  Reporting  .................  52 
8.4.1.  Time Period and Frequency  for Collecting AE and SAE Information  ...... 53 
8.4.1.1.  Reporting  SAEs to Pfizer Safety  ................................ ..............  53 
8.4.1.2.  Recording  Nonserious  AEs and SAEs  on the CRF ..................  53 
8.4.2.  Method  of Detecting  AEs and SAEs  ................................ ..........................  54 
8.4.3.  Follow -Up of AEs and SAEs  ................................ ................................ ..... 54 
8.4.4.  Regulatory  Reporting Requirements for SAEs  ................................ ..........  54 
8.4.5.  Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure  ................................ ....................  55 
8.4.5.1.  Exposure During Pregnancy  ................................ .....................  55 
8.4.5.2.  Exposure  During  Breastfeeding  ................................ ................  56 
8.4.5.3.  Occupational Exposure  ................................ .............................  57 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  6  
 8.4.6.  Cardiovascular  and Death  Events  ................................ ................................  57 
8.4.7.  Disease -Related  Events  and/or  Disease -Related  Outcomes  Not 
Qualifying  as AEs or SAEs  ................................ ................................ ..............  57 
8.4.8.  Adverse  Events  of Special  Interest  ................................ .............................  57 
8.4.8.1.  Lack of Efficacy  ................................ ................................ ........  57 
8.4.9.  Medical  Device  Deficiencies  ................................ ................................ ...... 57 
8.4.10.  Medication  Errors  ................................ ................................ ......................  58 
8.5. Pharmacokinetics  ................................ ................................ ................................ ..... 58 
8.5.1.  Plasma  for Analysis  of PF-07081532  ................................ ..........................  58 
8.5.2.  Plasma  for Determination  of PF-07081532  Unbound  Fraction  ..................  59 
8.6. Genetics  ................................ ................................ ................................ ...................  60 
8.6.1.  Specified  Genetics  ................................ ................................ .......................  60 
CCI  
8.7. Biomarkers  ................................ ................................ ................................ ...............  60 
CCI  
8.7.2.  Specified Gene Expression (RNA) Research  ................................ .............  60 
8.7.3.  Specified  Protein  Research  ................................ ................................ ..........  61 
8.7.4.  Specified  Metabolomic  Research  ................................ ................................  61 
8.8. Immunogenicity  Assessments  ................................ ................................ .................  61 
8.9. Health  Economics  ................................ ................................ ................................ .... 61 
9. STATISTICAL  CONSIDERATIONS  ................................ ................................ .................  61 
9.1. Statistical Hypotheses  ................................ ................................ ..............................  61 
9.2. Analysis  Sets ................................ ................................ ................................ ............  61 
9.3. Statistical Analyses  ................................ ................................ ................................ .. 62 
9.3.1.  General Considerations  ................................ ................................ ...............  62 
9.3.1.1.  Analyses  for PK Endpoints  ................................ ........................  62 
9.3.2.  Primary  Endpoint(s) Analysis  ................................ ................................ ..... 62 
9.3.2.1.  Definition of Endpoint(s)  ................................ ...........................  62 
9.3.2.2.  Main  Analytical  Approach  ................................ .........................  63 
9.3.2.3.  Supplementary  Analyses  ................................ ...........................  64 
9.3.3.  Secondary  Endpoint Analysis - Safety  Analyses  ................................ ........  64 
9.3.3.1.  Electrocardiogram Analyses  ................................ ......................  65 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  7  
  
 
 
 
 
 
9.4. Interim  Analyses  ................................ ................................ ................................ ..... 65 
9.5. Sample Size Determination  ................................ ................................ ....................  65 
10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  
CONSIDERATIONS ................................ ................................ ................................ ..........  67 
10.1. Appendix  1: Regulatory,  Ethical, and  Study  Oversight Considerations  ...............  67 
10.1.1.  Regulatory  and Ethical Considerations  ................................ ....................  67 
10.1.1.1.  Reporting of Safety Issues and Serious Breaches of the  
Protocol  or ICH GCP  ................................ ................................ ........  67 
10.1.2.  Financial Disclosure  ................................ ................................ .................  68 
10.1.3.  Informed  Consent  Process  ................................ ................................ ....... 68 
10.1.4.  Data  Protection  ................................ ................................ .........................  69 
10.1.5.  Committees  Structure  ................................ ................................ ...............  69 
10.1.5.1.  Data  Monitoring  Committee  ................................ ...................  69 
10.1.6.  Dissemination  of Clinical Study  Data ................................ ......................  70 
10.1.7.  Data  Quality  Assurance  ................................ ................................ ............  71 
10.1.8.  Source Documents  ................................ ................................ ...................  72 
10.1.9.  Study  and Site Start and Closure  ................................ ..............................  72 
10.1.10.  Publication Policy  ................................ ................................ ..................  73 
10.1.11.  Sponsor’s Medically  Qualified Individual  ................................ .............  74 
10.2. Appendix 2: Clinical Laboratory  Tests  ................................ ................................  75 
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording,  
Evaluating,  Follow -Up, and Reporting  ................................ ................................ ..... 77 
10.3.1.  Definition  of AE ................................ ................................ .......................  77 
10.3.2.  Definition  of an SAE ................................ ................................ ................  78 
10.3.3.  Recording/Reporting  and Follow -Up of AEs and/or  SAEs  During  
the Active Collection Period  ................................ ................................ ...........  79 
10.3.4.  Reporting of SAEs  ................................ ................................ ...................  83 
10.4. Appendix  4: Contraceptive  and Barrier  Guidance  ................................ ................  84 
10.4.1.  Male Participant Reproductive Inclusion Criteria  ................................ ... 84 
10.4.2.  Female Participant Reproductive Inclusion Criteria  ................................  84 CCI 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  8  
 10.4.3.  Woman  of Childbearing  Potential  ................................ ............................  84 
10.4.4.  Contraception  Methods  ................................ ................................ ............  85 
CCI  
10.6. Appendix  6: Liver  Safety:  Suggested  Actions  and Follow -Up Assessments  ....... 89 
10.7. Appendix 7: Kidney  Safety: Monitoring Guidelines  ................................ ............  91 
10.7.1.  Laboratory  Assessment of Change  in Kidney  Function  and 
Detection of Kidney Injury  ................................ ................................ .............  91 
10.7.2.  Age-Specific  Kidney  Function  Calculation Recommendations  ...............  91 
10.7.2.1.  Adults  (18 Years  and Above) —2021  CKD -EPI 
Equations13 ................................ ................................ ................................ ................................ ...... 91 
10.7.3.  Adverse  Event  Grading  for Kidney  Safety  Laboratory  
Abnormalities  ................................ ................................ ................................ .. 91 
10.8. Appendix  8: ECG  Findings  of Potential  Clinical  Concern  ................................ ... 92 
CCI  
10.10.  Appendix  10: Other  Prohibited  Prior/Concomitant  Medications  ........................  97 
10.11.  Appendix  11: Child -Pugh  Classification  (CPC)  of Liver  Dysfunction  ..............  98 
10.12.  Appendix  12: Abbreviations  ................................ ................................ ...............  99 
11. REFERENCES  ................................ ................................ ................................ ................  103 
 
LIST OF TABLES  
Table  1. Study  Schedule of Assessments  ................................ ...............................  17 
Table  2. Hepatic  Function  Categories  Based  on Child -Pugh  Score  .......................  26 
Table  3. Plasma  PK Parameters  ................................ ................................ .............  63 
Table  4. Expected  Widths  of the  90% CIs  (with 80%  Coverage Probability)  
for Different  Possible  Estimated  Effects  ................................ ...................  66 
Table  5. Protocol -Required  Safety  Laboratory  Assessments  ................................ .. 75 
Table  6. Scoring  for Child -Pugh Classification14 ................................ ................................ ..............  98 
Table  7. Derivation  of Child -Pugh  Classification  Score  ................................ .........  98 
Table  8. Determination of Encephalopathy  Grade  ................................ ..................  98 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  9  
 1. PROTOCOL  SUMMARY  
1.1. Synopsis 
Protocol  Title:  
A Phase  1, Open -Label,  Single -Dose,  Parallel  Group  Study  to Compare  the Pharmacokinetics 
of PF -07081532 in Adult Participants With Varying Degrees of Hepatic Impairment Relative 
to Participants Without Hepatic Impairment  
Brief  Title:  
A Study  to Investigate  the Effects  of Hepatic  Impairment  on the Pharmacokinetics  of 
PF-07081532  
Regulatory  Agency  Identification  Number(s):  
 
US IND Number:  CCI  
EudraCT/CTIS  Number:  NA 
ClinicalTrials.gov  ID: Not available  
Pediatric  Investigational  Plan  Number:  NA 
Protocol  Number:  C3991009  
Phase:  1 
Rationale:  
The primary purpose of this study is to characterize the effect of varying degrees of hepatic 
impairment  on the plasma  PK of PF-07081532  following  administration  of a single  oral dose 
of PF -07081532.  
Objectives  and Endpoints:  
 
Objectives  Endpoints  
Primary:  Primary:  
• To compare  the PK of PF-07081532  following  administration 
of a single  oral dose in adult  participants  with varying  degrees 
of hepatic impairment relative to age - and body  
weight -matched  participants  without  hepatic  impairment.  • Plasma:  Cmax, AUC inf, AUC last*, fu, Cmax,u, 
AUC inf,u and AUC last,u*, as data permit.  
Secondary:  Secondary:  
• To evaluate  the safety  and tolerability  of a single  oral dose of 
PF-07081532 when administered to adult participants with 
varying degrees of hepatic impairment and in age - and body 
weight -matched participants without hepatic impairment.  • Assessment  of treatment  emergent  AEs,  clinical 
laboratory abnormalities, vital signs, ECG 
parameters.  
* AUC last and AUC last,u  will be treated  as primary  endpoints  if data do not permit  robust  estimation  of AUC inf and AUC inf,u, 
otherwise they will be treated as tertiary endpoints.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  10  
 Overall  Design:  
This is an open -label, single -dose, parallel -group, multicenter study  to investigate  the effect 
of varying  degrees  of hepatic  function  on the plasma  PK of PF-07081532  after a single,  oral 
20 mg dose administered  in the fed state (standard  breakfast).  Safety  and tolerability  will be 
evaluated throughout the study.  
Number of Participants:  
Approximately  24 participants  will be enrolled  to receive  study  intervention.  
Note:  "Enrolled"  means  a participant's,  or their legally  authorized  representative’s,  agreement 
to participate in a clinical study following completion of the informed consent process and 
assignment to study intervention. A participant will be considered enrolled if the informed 
consent is not withdrawn prior to participating in any  study  activity  after screening. Potential 
participants who are screened for the purpose of determining eligibility for the study, but do 
not participate in the study, are not considered enrolled, unless otherwise specified by the 
protocol.  
Study Population:  
Key inclusion and exclusion  criteria are listed  below:  
Key Inclusion  Criteria  
Participants  must  meet  the following  key inclusion  criteria  to be eligible  for study 
enrollment:  
All Groups  
• Male  or female  between  the ages of 18 (or the minimum  country -specific  age of 
consent if >18) and 70 years, inclusive at the screening visit.  
• Willing  and able to comply  with all scheduled  visits,  treatment  plan,  laboratory  tests, 
lifestyle considerations, and other study procedures.  
• BMI  of 17.5 to 38.0  kg/m2, inclusive,  and a  total body  weight >50  kg (110 lb). 
• Capable  of giving  signed  informed  consent.  
Additional  for Group  1 Only  (without  Hepatic Impairment)  
• At screening, no clinically relevant abnormalities identified by a detailed medical 
history,  complete  PE, including  BP and pulse  rate measurement,  12-lead ECG  and 
clinical laboratory tests.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  11  
 • At screening,  meet  the demographic -matching  criteria,  including  body  weight  within  
±10 kg and age within  ±5 years,  of the average  of the pooled  hepatic  impairment 
groups, as provided by the sponsor.  
• No known  or suspected  hepatic  impairment  and meet  all the following  criteria  based 
on screening laboratory tests: ALT ≤ ULN, AST ≤ ULN, T bili ≤ ULN, Albumin  
≤ ULN,  PT ≤ ULN.  
Additional  for Groups  2, 3 & 4 Only (Hepatic  Impairment)  
• Stable  hepatic  impairment  that meets  criteria  for Class  A, B, or C of the Child -Pugh 
classification with no clinically significant change in disease status within 28 days 
before screening.  
• Stable  concomitant  medications  for the management  of individual  participant’s 
medical history.  
Key Exclusion  Criteria  
Participants  with any of the following  characteristics/conditions  will be excluded: 
All Groups  
• Any condition  possibly  affecting  drug absorption  (eg, prior  bariatric  surgery, 
gastrectomy, ileal resection).  
• At screening, a positive  result for HIV  antibodies.  
• Personal  or family  history  of MTC  or MEN2,  or participants  with suspected  MTC  per 
the investigator’s judgement.  
• History  of acute  pancreatitis  within  6 months  before  the screening  visit or any history 
of chronic pancreatitis.  
• Other  medical  or psychiatric  condition  or laboratory  abnormality  that may increase 
the risk of study participation or make the participant inappropriate for the study.  
• Use of specific  prohibited  prior/concomitant  therapies  as outlined  in the protocol.  
• Use of an investigational  product  within  30 days (or local  requirement)  or 5 half-lives 
(whichever longer), or 14 days plus 5 half -lives for strong CYP3A inducers or  
time-dependent  inhibitors,  before  study  dose.  
• eGFR<60  mL/min/1.73m2 (calculated  with the 2021  CKD -EPI Scr-Scys  combined 
equation) at screening.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  12  
 • A positive  urine  drug test at screening  or Day -1; however,  participants  in Groups  
2-4, only , who have been medically prescribed medications and report use at 
screening may be allowed after sponsor approval.  
• At screening  or Day -1, a positive  breath  alcohol  test. 
• For females,  pregnancy,  as indicated  by a positive  serum  pregnancy  test at screening 
and/or positive urine pregnancy test in WOCBP at Day -1. 
Additional  Group  1 Only  (without  Hepatic Impairment)  
• Evidence  of chronic  liver disease  including  history  of hepatitis,  hepatitis  B, or 
hepatitis C.  
• History  of alcohol  abuse  or binge  drinking  and/or  any other  illicit  drug use or 
dependence within 6 months of screening.  
• Screening  supine  12-lead ECG  demonstrating  QTcF  interval  >450  ms or a QRS 
interval >120 ms.  
• Screening  seated  SBP ≥140  mm Hg or DBP  ≥90 mm Hg, following  ≥5 minutes  of 
seated rest.  
• Use of chronic  prescription  medications  within  7 days or 5 half-lives  (whichever 
longer) before Day 1, or for prohibited medications, use within the required 
washout/restriction period in protocol.  
Additional  Exclusion  Criteria  for Groups  2, 3 & 4 Only  (Hepatic  Impairment)  
• Hepatic  carcinoma  or hepatorenal  syndrome  or limited  predicted  life expectancy 
(defined as <1 year in Groups 2 & 3 and <6 months for Group 4 only).  
• A diagnosis of hepatic dysfunction secondary to any acute ongoing hepatocellular 
process  that is documented  by medical  history,  PE, liver biopsy,  hepatic  ultrasound, 
CT scan, or MRI.  
• History  of surgery  that would  be expected  to alter absorption,  distribution, 
metabolism, or excretion properties of PF -07081532.  
• History  of gastrointestinal  hemorrhage  due to esophageal  varices  or peptic  ulcers  less 
than 4 weeks prior to screening.  
• Signs  of clinically  active  Grade  3 or 4 hepatic  encephalopathy  (ie, > Grade  2 Portal 
Systemic Encephalopathy score).  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  13  
 • Severe  ascites  and/or  pleural  effusion,  except  for those  categorized  in Group  4 who 
may be enrolled provided participant is medically stable, per the investigator’s 
judgment.  
• Previously  received  a kidney, liver,  or heart transplant.  
• Screening  supine  12-lead ECG  demonstrating  a QTcF  interval  >470  ms or a QRS 
interval >120 ms.  
• At screening,  Day -1 or pre-dose on Day 1, persistent  severe,  uncontrolled 
hypertension.  
• ALT  or AST  >5x ULN  on clinical  laboratory  tests at screening.  
Study Arms and Duration:  
A total of approximately 24 participants with varying degrees of hepatic function will be 
administered  a single,  oral 20 mg dose of PF-07081532  in the fed state as shown  in the table 
below.  
Hepatic  Function Categories  Based on Child -Pugh -Score  
 
Group  Description  Child -Pugh  Score  Number  of Participants  
1 Without  hepatic  impairment  Not Applicable  6a 
2 Mild  hepatic  impairment  Class  A (5 to 6 points)  6 
3 Moderate  hepatic  impairment  Class  B (7 to 9 points)  6 
4 Severe  hepatic  impairment  Class  C (10 to 15 points)  6b 
a. Additional participants may be dosed to a maximum of 8 participants to ensure mean age ±5 years and 
mean  body  weight  ±10 kg of this group  is aligned  with the pooled  average  assessed  when  approximately  
≥75%  of participants  are dosed  across  the other  3 groups.  
b. If recruitment  across  the sites selected  proves  to be prohibitive,  study may  dose 4-6 participants  in this 
group.  
 
Categorization  of participants  into Groups  2-4 will be done  based  on Child -Pugh  scores 
determined at the screening visit.  
Staged  Enrollment  of Study  Groups  
Participants  will be dosed  in a staged  manner  as follows:  
• Participants  with moderate  and severe  hepatic  impairment  (Groups  3 and 4) will be 
enrolled first.  
• Recruitment of participants with mild hepatic impairment (Group 2) will initiate 
when  approximately  50% of the participants  across  Groups  3 and 4 have  been  dosed.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  14  
 Sponsor  approval  is required  before  proceeding  with recruitment  of Group  2. 
• An average value for age and weight for the 3 hepatic impairment groups 
(Groups  2-4) will be determined  and participants  without  hepatic  impairment  
(Group  1) will be recruited  to match  the average  demographics  (at a minimum,  age 
and weight, and as much as practically possible gender) across the pooled  
Groups  2-4. 
• Recruitment  for healthy  participants  in Group  1 (without  hepatic  impairment)  may 
start when approximately 75% of total participants across Groups 2 -4 
(ie, approximately  12-13 participants)  have  been dosed.  
Sponsor  approval  is required  before  proceeding  with recruitment  of Group  1. 
For individual participants, the total duration of participation from the screening visit to the 
follow -up visit will range  from  approximately  5 weeks  (minimum)  to approximately  9 weeks 
(maximum). The study consists of an initial screening period of up to 28 days, a 7 -day 
inpatient stay at the CRU which includes administration of a single oral dose of  
PF-07081532,  and a follow  up contact  that will occur  28-35 days after PF-07081532 
administration.  
PF-07081532 will be supplied by Pfizer as 20 mg tablets in open -label bulk bottles along 
with individual dosing containers, as necessary, for unit dosing. For the 20 mg dose 
administered  in this study,  participants  will take 1 PF-07081532  20-mg tablet  orally  with the 
morning meal.  
 
Study Intervention(s)  
Intervention  Name  PF-07081532  
Arm  Name  
(group of participants receiving a 
specific  treatment  or no treatment)  Group  1, Group  2, Group  3, Group  4 
Unit  Dose  Strength(s)  20 mg 
Route  of Administration  Oral 
Use Experimental  
IMP or NIMP/AxMP  IMP 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  15  
  
Study  Arm(s)  
Arm  Title  Group  1 Group  2 Group  3 Group  4 
Arm  Type  Experimental  Experimental  Experimental  Experimental  
Arm  Participants  without  Participants  with Participants  with Participants  with 
Description  hepatic  impairment  mild hepatic  moderate  hepatic  severe  hepatic  
 will receive  a single  impairment  will impairment  will impairment  will 
 20 mg dose of receive  a single  receive  a single  receive  a single  
 PF-07081532,  20 mg dose of 20 mg dose of 20 mg dose of 
 administered  orally  PF-07081532,  PF-07081532,  PF-07081532,  
 as 1 PF-07081532  administered  orally  administered  orally  administered  orally  
 20 mg tablet  as 1 PF-07081532  as 1 PF-07081532  as 1 PF-07081532  
  20 mg tablet  20 mg tablet  20 mg tablet  
Statistical  Methods:  
A sample  size of approximately  24 participants  (approximately  6 participants  per group,  with 
varying degrees of hepatic function in each of the 4 groups) has been selected to provide 
sufficient precision to detect a 2 -fold difference in AUC inf between each Test group (with 
hepatic impairment) and the Reference group (without hepatic impairment).  
The effect  of varying  degrees  of hepatic  impairment  on PK parameters  will be assessed  by 
constructing 90% CI around the estimated difference between each of the Test (hepatic 
impaired) groups and the Reference (without hepatic impairment) group. A one -way 
ANOVA will be used to compare the natural log transformed PF -07081532 AUC inf, Cmax, 
AUC last, fraction unbound (fu), and associated unbound parameters (AUC inf,u, Cmax,u, 
AUC last,u  ), as data permit, for each of the hepatic impairment groups (Test) to the group 
without hepatic impairment (Reference). Estimates of the adjusted mean differences  
(Test  - Reference),  and corresponding  90% CIs, will be obtained  from  the model.  These  will 
be exponentiated to provide estimates of the ratio of adjusted geometric means 
(Test/Reference) and 90% CIs for the ratios.  
All safety analyses will be performed on the safety population. AEs, ECGs, BP, pulse rate, 
and safety laboratory  data will be reviewed and summarized on an ongoing basis during the 
study  to evaluate the safety  of participants. Any  clinical laboratory, ECG, BP, and pulse rate 
abnormalities  of potential  clinical  concern  will be described.  Safety  data will be presented  in 
tabular and/or graphical format and summarized descriptively, where appropriate following 
Sponsor standards.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  16  
 
Ethical  Considerations:  
A single dose of PF -07081532 administered in this study is not expected to provide any 
clinical benefit to study participants. This study is designed primarily to characterize the 
effect  of varying  degrees  of hepatic  impairment  on the PK of PF-07081532.  Results  from  this 
study will be used in conjunction with collective safety, tolerability, efficacy, and PK/PD 
data from other PF -07081532 studies to develop dosing recommendations for the target 
patient populations with varying degrees of hepatic function.  
1.2. Schema  
 
1.3. Schedule  of Activities  
The SoA table provides an overview of the protocol visits and procedures. Refer to the 
STUDY ASSESSMENTS AND PROCEDURES  section of the protocol for detailed 
information  on each procedure  and assessment  required  for compliance  with the protocol.  
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA 
table,  in order  to conduct  evaluations  or assessments  required  to protect  the well-being  of the 
participant.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  17  
 Table  1. Study  Schedule  of Assessments  
 
Visit  Identifier/Day  
[list of abbreviations in  Appendix  12] Screen  
≤-28 to -2 Day 
-1 Day 1 Day 2 Day 
3 Day 
4 Day 
5 Day 
6 Day 
7 ET Follow -upa 
Day 29-36 
Hours  Post Dose   -- 0 0.5 1 2 4 6 8 10 12 14 15 24 36 48 72 96 120 144 -- -- 
Informed  consent  & demography  x                      
COVID -19 testing/risk  assessmentb See footnote  
Outpatient visit x                      
Inpatient  stay at CRU   x → → → → → → → → → → → → → → → → → x   
Eligibility  assessment  x x x                    
Medical history  x                      
Child -Pugh  Classification  scoring  x                      
PE (height  & weight  at screening  only)c x x                  x x  
Breath  alcohol  & Urine  drug test x x                     
Alcohol/tobacco & contraception used x x                  x x x 
(Update) prior/concomitant treatments  x x → → → → → → → → → → → → → → → → → → x x 
Single,  supine  12-lead ECGe x  xe                 x x  
Single,  seated  vital signs  (BP, pulse  rate)e x x xe           x   x   x x  
AE monitoring  (non-serious  & SAEs)  x → → → → → → → → → → → → → → → → → → x x x 
Standard  meals/optional  snacksf  xf x    x x  x  x  x  x x x x x   
Study intervention administrationg   x                    
Blood  & Urine  for clinical  laboratory  testsh x  xk              x   x x  
Serology  for FSH (all females),  HIV, 
HBsAg, HCVAb/RNA  x                      
Serum  pregnancy test (all females)  x                      
Urine  pregnancy  test (WOCBP  only)i  x                  x x  
Prep D1.5  Retained  Research  Samplesj   xk                    
Blood  for PK sampling for PF -07081532    xk x x x x x x x x  x x x x x x x x x  
CCI     k                    
Blood  for fu of PF-07081532  in plasma    xk   x                 
a. Follow -up visit  to be performed  as telephone  contact  and must  occur  in the window  of 28 to 35 days (ie, Day 29-36) from  administration  of study  intervention.  A clinic  visit 
may be performed in place of telephone contact, if deemed necessary by the investigator, eg, for follow -up of abnormal laboratory tests and/or open AEs.  
b. Assessment  of risk for, symptoms  of or testing  for COVID -19 may be performed  at screening,  admission to  the CRU  and/or  at other  times  during  the study  at investigator 
discretion and according to local site policies.  
c. Complete  PE at  screening;  at all other  time points  limited  PE, at investigator  discretion  (see Section  8.3.1 ). 
d. In confirmation of appropriate contraception use only.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  18  
  
e. If done around the time of a blood draw, ECG and vital sign assessments (BP and pulse rate) should be collected before the bl ood draw. ECG and vital signs on Day 1 at 
Time  0H must  be done  before  collection  of the pre-dose blood  samples. If  an IV catheter  is utilized  for blood  sample  collections,  ECGs  and vital sign assessments  (BP and 
pulse rate) should be collected before insertion of the catheter.  
f. Meals/snacks  to be served  at clock  times  matching  approximately  0H, 4H, 6H (optional  snack),  10H,  and 14H (optional  snack)  relative  to dosing  on Day 1, while  inpatient. 
Meals/snacks on Day -1 must be timed such that there is at least an 8 hour fast prior to collection of the pre -dose PK sample on Day 1 (see Section 5.3.2 ). 
g. Dosing  to occur  with standard  morning meal  provided approximately  30 minutes prior  to 0H,  and meal  completed approximately  10 minutes  prior to dosing.  
h. Safety  related  laboratory  tests collected  on Day -1, if performed  at investigator  discretion,  must  be reviewed  prior  to dosing  and must  reflect  the participant  to be in stable 
medical condition.  
i. Test result must  be reviewed and deemed acceptable  (ie, negative)  to continue participation  in the  study.  
j. If not collected on  the designated  collection  day, collect  at the  next available  time point when  biospecimens  are collected  in conjunction  with a  participant visit.  
k. Samples  at Time  0 on Day 1 must  be collected  pre-dose.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  19  
 CCI 
CCI 2. INTRODUCTION  
GLP -1 is a neuroendocrine  hormone  that is predominantly  released  from  the small  intestine 
in response to food intake.1 Activation of the GLP -1R stimulates insulin release, inhibits 
glucagon secretion in a glucose -dependent manner, and delays gastric emptying.2,3 In 
addition, GLP -1 has been shown to increase satiety and suppress food intake.4 
PF-07081532  is a potent  and selective,  orally  administered,  small  molecule  GLP -1R agonist 
that is currently being developed as an adjunct to diet and exercise to improve glycemic 
control in adults with T2DM.  
2.1. Study Rationale  
The primary purpose of this study is to characterize the effect of varying degrees of hepatic 
impairment  on the plasma  PK of PF-07081532  following  administration  of a single  oral dose 
of PF -07081532.  
2.2. Background  
2.2.1.  Nonclinical  Pharmacology  
 
Details of the nonclinical pharmacology  program are included in the  IB. 
2.2.2.  Nonclinical  Pharmacokinetics  and Metabolism  
 
 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  20  
 
CCI 
CCI  
 
Further  details  of the nonclinical  PK and metabolism  program  are included  in the IB. 
2.2.3.  Nonclinical Safety  
PF-07081532  was administered  PO to Wistar  Han rats and cynomolgus  monkeys  in studies 
up to 6 and 9 months  in duration,  respectively.  All in vitro  and in vivo studies  used the Tris 
salt form of PF -07081532 (78% – 82.5% active moiety across all lots). The high dose  
(100 mg/kg/day  for rats and monkeys)  in the pivotal  toxicity  studies  were  selected  based  on 
toleration and findings from earlier repeat -dose and exploratory studies.  
 
 
The NOAELs in the 6 -month rat or 9 -month monkey pivotal toxicity studies were 
100 mg/kg/day  in both species,  with associated  unbound  Cmax and unbound  AUC 24 of 
and CCI 
respectively.  CCI in rats and CCI and CCI in monkeys,  
 
 
 
 
 
 
 
 
Further details of the nonclinical toxicology  program are included in the IB. 
2.2.4.  Clinical Overview  
Two clinical  studies  (C3991001  and C3991002)  have  been  completed  with PF-07081532  in 
which a total of 88 participants have been randomized. Across these 2 studies, 22 healthy 
adult participants, 51 adult participants with T2DM and 15 adult participants with obesity 
have been randomized, with a total of 74 unique participants exposed to at least 1 dose of 
PF-07081532.  CCI 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  21  
 CCI One Phase  1 study,  C3991003,  is ongoing.  This in-patient  study  is enrolling  participants  with 
T2DM inadequately controlled on metformin and participants with obesity to receive  
PF-07081532  or placebo  daily  for 42 days.  The starting  dose for the first cohort  of this study 
is 20 mg of PF -07081532, with subsequent dose levels to be determined based on emerging 
data, and dosing is in  progress.  While final  clinical data from this study  are not yet available 
as of issuance of this protocol, there have been no deaths, SAEs or AEs of severe intensity 
reported.  
2.2.4.1.  Clinical Safety  
The safety  profile  of PF-07081532  has been  assessed  in 2 completed  clinical  studies.  To date, 
administration of PF -07081532 at single doses up to 200 mg and multiple doses up to  
180 mg QD for up to 42 days has been considered safe, with a tolerability  profile consistent 
with the mechanism  of action.  The majority  of TEAEs  have  been  mild in intensity  and in the 
Gastrointestinal Disorders SOC.  
Following single dose administration  to healthy adult participants in study C3991001, the 
most frequently reported all -causality TEAEs across all treatment groups were nausea and 
vomiting,  with an increased  incidence  of gastrointestinal  AEs noted  at the dose of 200 mg. In 
the multiple ascending dose study, C3991002, the most frequently reported all causality 
TEAEs included nausea in participants with T2DM, and nausea and constipation in 
participants with obesity. Higher incidences of gastrointestinal TEAEs were observed in the 
higher dose groups of PF -07081532 (120 mg QD and 180 mg QD) compared to placebo.  
There  were  no clinically  significant  adverse  trends  in safety  laboratory  tests,  vital signs  or 
ECG parameters in either study with increasing PF -07081532 doses.  
Refer  to the IB for more  detail  on these  studies,  and the known  drug class  effects  of marketed 
GLP -1R agonists.  
2.2.4.2.  Clinical Pharmacokinetics  
The clinical  pharmacokinetics  of PF-07081532  have  been  evaluated  to date in 2 completed 
studies (C3991001 and C3991002), the results of which are provided in the IB.  
 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  22  
  
 
 CCI 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  23  
  
2.3. Benefit/Risk  Assessment  
More  detailed  information  about  the known  and expected  benefits  and risks  and reasonably  expected  AEs of PF-07081532,  and the 
drug class effects of marketed GLP -1R agonists, may be found in the IB, which is the SRSD for this study.  
2.3.1.  Risk  Assessment  
 
Potential  Risk  of Clinical 
Significance  Summary  of Data/Rationale  for Risk Mitigation  Strategy  
Study  Intervention  PF-07081532  
Gastrointestinal  adverse  reactions  The potential  risks  are based  on product  labeling  for injectable 
GLP -1R agonists (ie, liraglutide, exenatide, semaglutide and 
dulaglutide).  
In addition,  gastrointestinal  adverse  events,  the majority  of which 
were  mild in severity,  have  been  observed  in the clinical  program 
with PF -07081532.  The single  dose and dose level  administered  in 
this study minimize any potential risk.  
Participants are monitored during the clinical 
studies to prevent potential sequelae of any 
severe  gastrointestinal  reactions,  eg, dehydration.  
Hypoglycemia  Clinical trials with injectable GLP -1R agonists have not 
demonstrated  an increased  risk for hypoglycemia.  However,  when 
administered in combination with anti -diabetic agents that are 
known  to have  an increased  risk of hypoglycemia  (such  as insulin 
or sulfonylureas), an increased risk for hypoglycemia was 
observed.  The single  dose and dose level  administered  in 
this study minimize any potential risk.  
Study includes inpatient monitoring of the 
participants  following  administration  of a single 
dose of the investigational product.  
Increased  heart  rate Based on the product labeling for the injectable GLP -1R agonist 
liraglutide  for obesity,  mean  increases  in resting  heart  rate ranged  2 
to 3 bpm in clinical trials, with some participants experiencing 
greater increases in resting heart rate, up to 10 -20 bpm.  
Following single dose administration of PF -07081532 in the 
completed FIH study, variable increases in heart rate were 
observed;  the majority  of individual  values  remained  within  normal 
ranges, and, throughout the study, no AEs or clinical symptoms 
related to vital sign parameters were reported.  The single  dose and dose level  administered  in 
this study minimize any potential risk.  
Study includes inpatient monitoring of the 
participants  following  administration  of a single 
dose of the investigational product.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  24  
  
Potential  Risk  of Clinical 
Significance  Summary  of Data/Rationale  for Risk Mitigation  Strategy  
Potential  risks  associated  with 
long-term dosing of marketed 
GLP -1R agonists include  
thyroid  C-cell tumors,  pancreatitis, 
impairment in renal function, 
diabetic  retinopathy  complications, 
acute gallbladder disease,  The potential  risks  are based  on product  labeling  for injectable 
GLP -1R agonists (ie, liraglutide, dulaglutide, exenatide and 
semaglutide); additional information is provided in the IB.  The single  dose and dose level  administered  in 
this study minimize any potential risk.  
Study includes inpatient monitoring of the 
participants  following  administration  of a single 
dose of the investigational product.  
Participants  with a personal  or family  history  of 
medullary thyroid carcinoma or MEN2; with 
acute pancreatitis or a history of chronic 
pancreatitis are not eligible for study entry.  
Other  
Risk of COVID -19 exposure  during 
study.  During the pandemic, study participants could be exposed to the 
SARS -CoV -2 virus  during  study  participation.  This could  lead to 
increased health risk for this participant and others in the study.  Assessment  of risk for, symptoms  of or testing 
for COVID -19 may be performed  at screening, 
admission to the CRU and/or at other times 
during the study at investigator discretion and 
according to local site policies.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  25  
 2.3.2.  Benefit  Assessment  
A single dose of PF -07081532 is not expected to provide any clinical benefit to study 
participants.  This study  is designed  primarily  to characterize  the effect  of varying  degrees  of 
hepatic impairment on the PK of PF -07081532 to support further clinical development of 
PF-07081532 as a potential treatment of T2DM. Results from this study will be used in 
conjunction with collective safety, tolerability, efficacy, and PK/PD data from other  
PF-07081532  studies  to develop  dosing  recommendations  for the target  patient  population 
with varying degrees of hepatic function.  
2.3.3.  Overall  Benefit/Risk  Conclusion  
In line with the clinical  profile  of marketed  GLP -1R agonists,6 the most  frequently  reported 
AEs in the 2 completed clinical studies with PF -07081532 administration have been in the 
Gastrointestinal Disorders SOC ( Section 2.2.4 ). In addition, as has been reported for 
marketed GLP -1R agonists,7,8 modest increases in heart rate have been observed with  
PF-07081532  administration,  with most  heart  rate values  within  the normal  range.  Based  on 
available clinical data ( Section 2.2.4  and current IB), a single 20 mg PF -07081532 dose is 
anticipated to be safe and well tolerated, including in participants with varying degrees of 
hepatic impairment, even if increased plasma concentrations were to be observed  
(Section  4.3). 
Based  on the profile  of PF-07081532  observed  in nonclinical  and clinical  studies  to date,  and 
taking into account the measures to minimize risk to study participants, the potential risk to 
the participants in this study is deemed to be minimal and is justified by the anticipated 
benefits that may be afforded to patients with varying degrees of hepatic impairment 
receiving PF -07081532 in the future.  
3. OBJECTIVES  AND  ENDPOINTS  
 
Objectives  Endpoints  
Primary:  Primary:  
• To compare  the PK of PF-07081532  following  administration 
of a single  oral dose in adult  participants  with varying  degrees 
of hepatic impairment relative to age - and body  
weight -matched  participants  without  hepatic impairment.  • Plasma:  Cmax, AUC inf, AUC last*, fu, Cmax,u, 
AUC inf,u and AUC last,u*, as data permit.  
Secondary:  Secondary:  
• To evaluate  the safety  and tolerability  of a single  oral dose of 
PF-07081532 when administered to adult participants with 
varying degrees of hepatic impairment and in age - and body 
weight -matched participants without hepatic impairment.  • Assessment  of treatment  emergent  AEs,  clinical 
laboratory abnormalities, vital signs, ECG 
parameters.  
CCI     
 
    
 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  26  
  
Objectives  Endpoints  
•  CCI   
  
* AUC last and AUC last,u  will be treated  as primary  endpoints  if data do not permit  robust  estimation  of AUC inf and AUC inf,u, 
otherwise they will be treated as tertiary endpoints.  
 
4. STUDY  DESIGN  
4.1. Overall  Design  
This is an open -label, single -dose, parallel -group, multicenter study to investigate the effect 
of varying degrees of hepatic function on the plasma PK of PF -07081532 after a single, oral 
20 mg dose administered  in the fed state (standard  breakfast).  Safety  and tolerability  will be 
evaluated throughout the study. A total of approximately 24 participants with varying 
degrees of hepatic function will be dosed in the study  as shown in Table 2. If recruitment of 
participants  with severe  hepatic  impairment  proves  prohibitive,  the number  of participants  to 
be enrolled in this group may be flexible (4 -6 participants).  
Table  2. Hepatic  Function Categories Based  on Child -Pugh  Score  
 
Group  Description  Child -Pugh  Score  Number  of Participants  
1 Without  hepatic  impairment  Not Applicable  6a 
2 Mild  hepatic  impairment  Class  A (5 to 6 points)  6 
3 Moderate  hepatic  impairment  Class  B (7 to 9 points)  6 
4 Severe  hepatic  impairment  Class  C (10 to 15 points)  6b 
a. Additional participants may be dosed to a maximum of 8 participants to ensure mean age ±5 years and 
mean  body  weight  ±10 kg of this group  is aligned  with the pooled  average  assessed  when  approximately  
≥75%  of participants  are dosed  across  the other  3 groups.  
b. If recruitment  proves  to be prohibitive,  study  may dose 4-6 participants  in this group.  
 
Categorization  of participants  into Groups  2-4 will be done  based  on Child -Pugh  scores 
determined, as described in Appendix 11  at the screening visit.  
Staged  Enrollment  of Study  Groups  
Participants  will be dosed  in a staged  manner  as follows:  
• Participants  with moderate  and severe  hepatic  impairment  (Groups  3 and 4) will be 
enrolled first.  
• Recruitment of participants with mild hepatic impairment (Group 2) will initiate 
when  approximately  50% of the participants  across  Groups  3 and 4 have  been  dosed.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  27  
 Sponsor  approval  is required  before  proceeding  with recruitment  of Group  2. 
• An average value for age and weight for the 3 hepatic impairment groups 
(Groups  2-4) will be determined,  and participants  without  hepatic  impairment  
(Group  1) will be recruited  to match  the average  demographics  (at a minimum,  age 
and weight, and as much as practically possible gender) across the pooled  
Groups  2-4. 
• Recruitment  for healthy  participants  in Group  1 (without  hepatic  impairment)  may 
start when approximately 75% of total participants across Groups 2 -4 
(ie, approximately  12-13 participants)  have  been dosed.  
Sponsor  approval  is required  before  proceeding  with recruitment  of Group  1. 
Participants  who prematurely  discontinue  before  completing  all assessments  may be 
replaced, at the discretion of the investigator and sponsor study team.  
The overall study design is presented as a schematic in Section 1.2 . For individual 
participants,  the total duration  of participation  from  the screening  visit to the follow -up visit 
will range from approximately 5 weeks (minimum) to approximately 9 weeks (maximum). 
The study consists of an initial screening period of up to 28 days,  a 7-day inpatient stay at 
the CRU which includes administration of a single oral dose of PF -07081532, and a  
follow  up contact  that will occur  28-35 days after PF-07081532  administration.  
4.2. Scientific Rationale for  Study Design  
The purpose of this study is to characterize the effect of varying degrees of hepatic 
impairment  on the  PK, safety  and tolerability  of PF-07081532. PF -07081532  is an oral 
GLP -1R agonist  that is currently  being  investigated  as a chronic  therapy  to improve  glycemic 
control  in adult  participants  with T2DM.  Based  on review  of the effect  of hepatic  impairment 
on human PK CCI 
impaired  hepatic  function  is generally  associated  with increased  drug 
exposures in plasma CCI 
 
 
 
As such, this study will enroll participants with varying degrees of hepatic 
impairment, and participants without hepatic impairment (matched for age as well as body 
weight and gender as much as practically possible) in order to allow a robust assessment of 
PK across the entire spectrum of hepatic function. A single dose of PF -07081532 is  
proposed,  as single  dose plasma  PK of PF-07081532  is generally  predictive  of exposure  upon 
repeated dosing.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  28  
 CCI 
CCI Following administration of single oral doses of PF -07081532 under either fasted or fed 
conditions in Study C3991001 (non -Japanese cohorts), the arithmetic mean terminal t ½ of 
PF-07081532  ranged  approximately  from  17 to 21 hours.  Therefore,  in this study,  serial  PK 
samples will be collected up to 144 hours post -dose in order to allow adequate  
characterization  of the elimination  phase  of the plasma  concentration -time profile  should  any 
increased half -life (up to 2 -fold) in participants with varying degrees of hepatic impairment 
be observed.  
Available PK data with PF -07081532 administered under fasted or fed conditions indicate 
that PF-07081532  may be administered  without  regard  to food. In  this study,  a single  dose of 
PF-07081532 will be administered with a standard breakfast to reflect the conditions for 
anticipated use of PF -07081532 in future trials and the target patient population.  
PF-07081532  is extensively  bound  to plasma  proteins  with a fu of 0.000376  in humans  and, 
as such, plasma protein binding may be affected in patients with chronic liver disease. To 
assess the in vivo protein binding of PF -07081532 with varying degrees of hepatic 
impairment, the fu of PF -07081532 will be determined in all participants at approximately 
the expected T max. 
 
In general, participants with normal hepatic function (Group 1) will abstain from 
concomitant treatments, except for the treatment of adverse events. Use of selected limited 
prescription and non -prescription medications may be permitted (refer to Section 6.9  for 
details). Participants with impaired hepatic function (Groups 2, 3 and 4) are permitted to be 
on stable  doses  of background  medications  for the management  of their concomitant  medical 
condition(s) with some exclusions (see Appendix 9 and Appendix 10 ). 
 
To minimize the risks of COVID 19 related complications to participants and the study site 
personnel,  assessment  of risk for, symptoms  of or testing  for COVID -19 may be performed  at 
screening, admission to the CRU and/or at other times during the study at investigator 
discretion and according to local site policies.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  29  
 CCI The Child -Pugh  Classification  (CPC;  refer  to Appendix  11) will be used to define  the 
3 groups  of participants  with varying  degrees  of hepatic  impairment.  This study  will include 
participants with mild (Child -Pugh Class A, Group 2), moderate (Child -Pugh Class B, 
Group 3), and severe (Child -Pugh Class C, Group 4) hepatic impairment as well as 
demographically matched control participants without hepatic impairment (Group 1). All 
participants will be required to provide their own consent to participate in this study, hence 
participants with clinically active Grade 3 or Grade 4 encephalopathy will be excluded.  
However, participants who have a previous history of Grade 3 or 4 encephalopathy but are 
currently receiving an intervention (eg, lactulose or lactitol, alone or in combination with 
rifaximin, and/or neomycin) to manage their encephalopathy -related signs and symptoms are 
eligible  provided  the on-treatment  encephalopathy  grading  at the screening  visit is Grade  2 or 
lower, thereby permitting them to provide their own informed consent. Acknowledging the 
medical state of the population enrolled, certain eligibility criteria for participants with 
hepatic impairment are distinctly different, with no specific exclusion of participants with 
Hepatitis B and Hepatitis C in Groups 2, 3, or 4.  
Although  urinary  recovery  of PF-07081532  is low, with less than 0.2%  of the dose recovered 
in the 24 -hour dosing interval ( Section 2.2.4.2 ), 
10 Therefore,  in order  to 
enable a robust assessment of the effect of hepatic impairment on PF -07081532 PK, 
participants  will be excluded  if there  is concomitant  clinical  evidence  of renal  impairment, 
defined as eGFR <60 mL/min/1.73m2. 
4.2.1.  Choice of Contraception/Barrier Requirements  
Both women of childbearing potential, as well as those who are of non -childbearing 
potential, may be enrolled given the availability of EFD toxicity studies with PF -07081532. 
However,  as marketed  GLP -1R agonists  are listed  as contraindicated  in pregnancy,  measures 
will be taken to limit the risk of pregnancy in the female population enrolled (see SoA and 
Section 10.4 ). 
The potential risk of exposure to PF -07081532 in a sexual partner of a male participant in 
this study via ejaculate is low, and therefore no contraception (condom) use in male 
participants is warranted.  The calculated safety margin is ≥100 fold between the estimated 
partner exposure due to seminal transfer and the NOAEL for serious manifestations of 
developmental toxicity in nonclinical studies.  The safety margin of 100 fold is based on 
applying  a 10 fold safety  factor  for interspecies  extrapolation  and a 10 fold safety  factor  for 
susceptible populations.11 
4.2.2.  Collection  of Retained  Research  Samples  
Retained  Research  Samples  will be collected  and stored  for further  analyses  which  may,  for 
example, provide greater understanding of the study intervention.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  30  
 4.3. Justification for Dose  
A single oral dose of 20 mg will be used in this study. This dose has been selected based on 
prior experience in clinical studies with PF -07081532 ( Section 2.2.4 ) and also taking into 
account  safety  considerations  for the participants  with varying  degrees  of hepatic  impairment 
in whom an increase in plasma PF -07081532 exposure may be observed.  
In Study C3991001, a single dose of 30 mg was very well tolerated with an AE profile that 
did not differ from placebo. In the same study, single ascending doses up to 200 mg were 
tested  and were  considered  safe and had a tolerability  profile  in line with expectations  for the 
mechanism of action, with the majority of AEs being mild in severity and in the 
Gastrointestinal Disorders SOC (with nausea and vomiting the most frequently observed).  
For participants  that experienced  vomiting  (observed  at the 100 and 200 mg dose levels,  with 
increased incidence at 200 mg), this generally  occurred after the attainment of C max and with 
no apparent impact on PF -07081532 exposure. In addition, the dose proposed in the current 
study (20 mg) reflects adequate safety margins compared to nonclinical toxicity studies.  
After  accounting  for species  differences  in plasma  protein  binding,  this dose represents  an 
exposure in participants with healthy hepatic function that is approximately CCI  
for C max and AUC respectively, lower than the exposure observed at the NOAEL in 
the pivotal 9 -month toxicology study in monkeys ( Section 2.2.3 ). Given the above, it is 
anticipated  that potential  increases  in plasma  exposure  in participants  with varying  degrees  of 
hepatic impairment in the current study, if encountered, are not anticipated to pose an undue 
safety risk.  
Although  doses  up to  260 mg  QD may be evaluated in  future  clinical  studies with 
PF-07081532,  the proposed  dose of 20 mg is viewed  as appropriate  for this study,  given  the 
potential of increased exposures in participants with hepatic impairment. Since no greater 
than dose -proportional increases in exposure of PF -07081532 have been observed over the 
range  of clinical  doses  tested  so far (up to single  dose of 200 mg and up to 180 mg QD),  the 
results from this study may be used to extrapolate and inform the effect of hepatic 
impairment on PK for doses exceeding 20 mg.  
4.4. End of Study Definition  
The end of the study  is defined  as the date of the follow  up visit as shown  in the SoA for the 
last participant in the trial globally.  
A participant  is considered  to have  completed  the study  if they have  completed  all phases  of 
the study, including the follow up visit (telephone contact or onsite visit per Investigator 
discretion) as shown in the SoA. 
5. STUDY POPULATION  
This study can fulfill its objectives only if appropriate participants are enrolled, including 
participants across diverse and representative racial and ethnic backgrounds. Use of a 
prescreening tool is utilized for study recruitment purposes, it will include collection of 
information  that reflects  the enrollment  of a diverse  participant  population  including,  where  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  31  
 permitted  under  local  regulations,  age, sex, and race,  and ethnicity.  The following  eligibility 
criteria are designed to select participants for whom participation in the study  is considered 
appropriate. All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular participant is suitable for this protocol.  
Prospective  approval  of protocol  deviations  to recruitment  and enrollment  criteria,  also 
known as protocol waivers or exemptions, is not permitted.  
5.1. Inclusion  Criteria  
Participants  are eligible  to be included  in the study  only if all of the following  criteria  apply:  
5.1.1.  Participants  in All Groups 
Age and Sex:  
1. Male  or female  between  the ages of 18 (or the minimum  country -specific  age of 
consent if >18) and 70 years, inclusive, at the screening visit.  
Women may be of child -bearing potential, however, cannot be pregnant, 
breastfeeding,  or planning  to become  pregnant  while  participating  in the study.  Refer 
to Appendix 4  for reproductive criteria for male ( Section 10.4.1 ) and female  
(Section 10.4.2 ) participants.  
Other Inclusion  Criteria:  
2. Willing  and able to comply  with all scheduled  visits,  treatment  plan,  laboratory  tests, 
lifestyle considerations (as described in Section 5.3 ), and other study procedures.  
3. BMI of 17.5 to 38.0 kg/m2, inclusive; and a total body weight >50 kg (110 lb), at the 
screening  visit;  with a single  repeat  assessment  of total body  weight  (and hence  BMI), 
on a separate day  before Day -1 permitted to assess eligibility, if needed.  
4. Capable of giving signed informed consent as described in Appendix 1 , which 
includes  compliance  with the requirements  and restrictions  listed  in the ICD and in 
this protocol.  
5.1.2.  Additional  Inclusion  Criteria  for Group  1 Only  (without  Hepatic  Impairment)  
1. At screening, no clinically relevant abnormalities identified by a detailed medical 
history,  complete  PE, including  BP and pulse  rate measurement,  12-lead ECG  and 
clinical laboratory tests, as assessed by the sponsor approved laboratory.  
2. At screening,  participants  must  meet  the demographic -matching  criteria,  including:  
• A body  weight  that is within  ±10 kg of the average  of the pooled  hepatic 
impairment groups (Groups 2, 3, and 4), as provided by the sponsor;  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  32  
 • An age that is within  ±5 years  of the average  of the pooled  hepatic  impairment 
groups (Groups 2, 3, and 4), as provided by the sponsor;  
• Attempts  will be made  to ensure  that the male -to-female  distribution  in Group  1 is 
comparable to that in the pooled hepatic impairment groups (Groups 2, 3, and 4).  
3. No known  or suspected  hepatic  impairment,  and meet  all the following  criteria  at 
screening, as assessed by the sponsor approved laboratory, with a single repeat 
permitted to assess eligibility, if needed:  
• ALT  ≤ ULN;  
• AST  ≤ ULN;  
• T bili ≤  ULN;  
NOTE : Participants with a history of Gilbert syndrome (and hence elevated T bili) 
are eligible  provided  direct  bilirubin  level  is ≤ ULN  plus ALT  and AST  are ≤ ULN 
plus alkaline phosphatase, hemoglobin, and reticulocyte count are all ≤ ULN.  
• Albumin  ≤ ULN;  
• PT ≤ ULN.  
5.1.3.  Additional  Inclusion  Criteria  for Groups  2, 3 & 4 Only  (Hepatic  Impairment)  
1. Stable  hepatic  impairment  that meets  the criteria  for Class  A, B, or C of the 
Child -Pugh  classification  (refer  to Appendix  11) with no clinically  significant  change 
in disease status within the 28 days prior to the screening visit, as documented by  the 
participant’s recent medical history (eg, no worsening clinical signs of hepatic 
impairment, no worsening of T bili or PT by more than 50%).  
2. Stable concomitant medications for the management of individual participant’s 
medical  history;  on a case-by-case basis , with approval  from  the sponsor,  participants 
receiving fluctuating concomitant medication/treatment may be considered if the 
underlying disease is under control.  
5.2. Exclusion  Criteria  
Participants  are excluded  from  the study  if any of the following  criteria  apply:  
5.2.1.  Participants  in All Groups 
Medical Conditions:  
1. Any condition  possibly  affecting  drug absorption  (eg, prior  bariatric  surgery, 
gastrectomy, ileal resection).  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  33  
 
CCI NOTE:  Participants  who have  undergone  cholecystectomy  and/or  appendectomy  are 
eligible for this study as long as the surgery occurred more than 6 months prior to 
screening.  
2. At screening,  a positive  result  for HIV antibodies,  as assessed  by sponsor  approved 
laboratory, with a single repeat permitted to assess eligibility, if needed.  
3. Personal  or family  history  of MTC  or MEN2,  or participants  with suspected  MTC  per 
the investigator’s judgement.  
4. History  of acute  pancreatitis  within  6 months  before  the screening  visit or any history 
of chronic pancreatitis.  
5. Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory abnormality or other conditions or 
situations  related  to COVID -19 pandemic  (eg, contact  with positive  case)  that may 
increase  the risk of study participation  or, in  the investigator’s  judgment, make  the 
participant inappropriate for the study.  
Prior/Concomitant Therapy:  
6. Use of specific  prohibited  prior/concomitant  therapies  as outlined  in Section  6.9, 
Appendix 9  and Appendix 10 . 
Prior/Concurrent Clinical Study Experience:  
7. Previous  administration  with an investigational  product  (drug  or vaccine)  within  
30 days (or as determined  by the local  requirement)  or 5 half-lives  preceding  the first 
dose of study intervention used in this study (whichever is longer).  
 
 
8. Known  prior  participation  (ie, received  at least 1 dose of study  intervention)  in a 
study involving PF -07081532.  
Diagnostic Assessments:  
9. eGFR < 60 mL/min/1.73m2 (calculated with the 2021 CKD -EPI Scr -Scys combined 
equation,  see Appendix  7), at the screening  visit,  as assessed  by the sponsor  approved 
laboratory, and confirmed by a single repeat test, if deemed necessary.  
10. A positive  urine  drug test at screening  or Day -1. However,  participants  in 
Groups 2 -4, only , who have been medically prescribed medications,  
eg, opiates/opioids,  cannabinoids,  benzodiazepines,  methylphenidate  (or similar),  and 
report the use of these drugs to the investigator at the screening visit may  be allowed 
to participate, after approval from the sponsor, and if in line with protocol  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  34  
 specifications  regarding  prohibited  medications  (see Section  6.9, Appendix  9 and 
Appendix 10 ). 
NOTE : repeat  urine  drug testing  to assess  study  eligibility  at screening  or Day  -1 is 
not permitted in this study.  
11. At screening  or Day -1, a positive  breath  alcohol  test, as assessed  using  kits approved 
by sponsor; for the screening test, a single repeat (which may be on a separate day) 
before Day -1 is permitted to assess eligibility, if needed.  
12. For females,  pregnancy,  as indicated  by a positive  serum  pregnancy  test at screening 
and/or positive urine pregnancy test in WOCBP at Day -1. 
13. If performed at investigator discretion, safety related laboratory tests collected on 
Day -1, upon  review  prior  to dosing  reflect  the participant  not to be in stable  medical 
condition.  
Other Exclusion  Criteria:  
14. Blood  donation  (excluding  plasma  donations)  of approximately  1 pint (500 mL) or 
more within 60 days prior to dosing and until the follow -up contact.  
15. History  of sensitivity  to heparin  or heparin -induced  thrombocytopenia,  only if heparin 
is used to flush IV catheters used during serial blood collections.  
16. Investigator site staff directly involved in the conduct of the study and their family 
members,  site staff otherwise  supervised  by the investigator,  and sponsor  and sponsor 
delegate employees directly involved in the conduct of the study and their family 
members.  
5.2.2.  Additional  Exclusion  Criteria  for Group  1 Only  (without  Hepatic  Impairment)  
1. Evidence of chronic liver disease including history of hepatitis, hepatitis B, or 
hepatitis  C or evidence  of any of the following,  as assessed  by sponsor  approved 
laboratory, with a single repeat, permitted to assess eligibility, if needed:  
• Hepatitis  B virus,  defined  by presence  of HBsAg;  
NOTE:  while  not part of the tests assessed  in this study,  a previously  positive 
hepatitis B surface antibody result due to vaccination is permissible.  
• Hepatitis  C infection, defined by  presence  of HCVAb and HCV  RNA.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  35  
 2. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of screening. Binge drinking is defined as a pattern of 
5 (male)  and 4 (female)  or more  alcoholic  drinks  in about  2 hours.  As a general  rule, 
alcohol  intake  should  not exceed  14 units  per week  (1 unit = 8 ounces  (240 mL) beer, 
1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).  
3. Screening supine  12-lead ECG demonstrating QTcF interval >450 ms or a QRS 
interval  >120  ms. If QTcF  exceeds  450 ms, or QRS  exceeds  120 ms, the ECG  should 
be repeated 2 more times and the average of the 3 QTcF or QRS values should be 
used to determine the participant’s eligibility.  
4. Screening seated  SBP ≥140 mm Hg or DBP ≥90 mm Hg, following ≥5 minutes of 
seated rest. If SBP is ≥140 mm Hg or DBP ≥90 mm Hg, the BP assessment should be 
repeated  2 more  times  and the average  of the 3 BP values  should  be used to determine 
eligibility.  
5. Use of chronic  prescription  medications  within  7 days or 5 half-lives  (whichever  is 
longer) prior to Day 1, or for prohibited medications, use within the required 
washout/restriction period provided in Appendix 9  and Appendix 10 . 
NOTE:  Use of selected,  limited  prescription  and non-prescription  medications  may 
be permitted on a case -by-case basis  after approval from the sponsor (refer to 
Section 6.9  for details).  
5.2.3.  Additional  Exclusion  Criteria  for Groups  2, 3 & 4 Only  (Hepatic  Impairment)  
1. Hepatic  carcinoma  or hepatorenal  syndrome  or limited  predicted  life expectancy 
(defined as <1 year in Groups 2 & 3 and <6 months for Group 4 only).  
2. A diagnosis of hepatic dysfunction secondary to any acute ongoing hepatocellular 
process  that is documented  by medical  history,  PE, liver biopsy,  hepatic  ultrasound, 
CT scan, or MRI.  
3. History of surgery that would be expected to alter absorption, distribution, 
metabolism,  or excretion  properties  of PF-07081532  (eg, status  post porta -caval  shunt 
surgery).  
NOTE:  Participants  with a transjugular  intrahepatic  portosystemic  shunt  are 
permitted provided that they meet the Child -Pugh criteria.  
4. History  of gastrointestinal  hemorrhage  due to esophageal  varices  or peptic  ulcers  less 
than 4 weeks prior to the screening visit.  
5. Signs  of clinically  active  Grade  3 or 4 hepatic  encephalopathy  (ie, > Grade  2 Portal 
Systemic Encephalopathy score; refer to Appendix 11 ). 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  36  
 6. Severe  ascites  and/or  pleural  effusion,  except  for those  categorized  in Group  4 who 
may be enrolled provided participant is medically stable, per the investigator’s 
judgment.  
7. Previously  received  a kidney, liver,  or heart transplant.  
8. Screening supine  12-lead ECG demonstrating a QTcF interval >470 ms or a QRS 
interval  >120  ms. If QTcF  exceeds  470 ms, or QRS  exceeds  120 ms, the ECG  should 
be repeated 2 more times and the average of the 3 QTcF or QRS values should be 
used to determine eligibility.  
9. At screening,  Day -1 or pre-dose on Day 1, persistent  severe,  uncontrolled 
hypertension as outlined below:  
• Groups  2, 3 and 4 at screening  or Day -1: seated  SBP ≥180  mm Hg or 
DBP  ≥105  mm Hg after ≥5-minute  of seated  rest, with a single  repeat  permitted  to 
assess eligibility, if needed, at each of these 2 visits;  if done, the repeat 
assessment overrides initial results.  
NOTE : For participants  with SBP ≥160  and ≤179  mm Hg or DBP  ≥100  and 
≤104  mm Hg at screening,  the period  between  screening  and Day -1 may be used 
to refine the doses of the agents used for management of BP with the aim of 
having stable BP by Day -1. 
• Groups  2 and 3 only, at Day 1: seated  SBP ≥160  mm Hg or DBP  ≥100  mm Hg 
after ≥5-minute  of seated  rest, with a single  repeat  permitted  to assess  eligibility, 
if needed; if done, the repeat assessment overrides initial results.  
• Group  4 only, at Day 1: seated  SBP ≥ 160 mm Hg or DBP  ≥105  mm Hg after 
≥5-minute  of seated  rest, with a single  repeat  permitted  to assess  eligibility,  if 
needed; if done, the repeat assessment overrides initial results.  
10. ALT  or AST  >5x ULN  on clinical  laboratory  tests at screening,  as assessed  by the 
sponsor  approved  laboratory,  with a single  repeat  permitted  to assess  eligibility,  if 
needed.  
5.3. Lifestyle Considerations  
After  confirmation  of eligibility,  participants  will be instructed  to maintain  the guidelines 
described below for the duration of participation in the study.  
5.3.1.  Contraception  
The investigator  or their designee,  in consultation  with the participant,  will confirm  that the 
participant  is utilizing  an appropriate  method  of contraception  for the individual  participant 
from the permitted list of contraception methods (see Appendix 4 , Section 10.4.4 ) and will 
confirm that the participant has been instructed in its consistent and correct use. At time  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  37  
 points  indicated  in SoA, the investigator  or designee  will inform  the participant  of the need  to 
use highly effective contraception consistently and correctly and document the conversation 
and the participant’s affirmation in the participant’s chart. Participants need to affirm their 
consistent and correct use of at least 1 of the selected methods of contraception, considering 
that their risk for pregnancy may have changed since the last visit.  
In addition, the investigator or designee will instruct the participant to call immediately  if the 
selected contraception method is discontinued and document the requirement to use an 
alternate  protocol -specified method, including if the participant will no longer use abstinence 
as the selected  contraception  method,  or if pregnancy  is known  or suspected  in the participant 
or partner.  
5.3.2.  Meals  and Dietary  Restrictions  
• Participants  must  abstain  from  all food and drink (except water) at least 4  hours prior 
to all fasting  clinical  laboratory  evaluations  and at least 8 hours  prior  to the collection 
of the pre -dose PK sample on Day 1.  
• Water may  be consumed as desired (ad libitum).  
• While inpatient, all meals will be standardized as follows:  
• On Day 1, following an overnight fast of at least 8 hours, participants should 
begin  breakfast  approximately  30 minutes  prior  to PF-07081532  administration. 
The breakfast will be consumed over approximately a 20 -minute period with  
PF-07081532  administered  within  approximately  10 minutes  after completion  of 
the meal.  Participants  will be encouraged  to complete  the entire  breakfast.  There 
will be no water restrictions prior to dosing.  
• Standard  morning  meal,  lunch,  an optional  afternoon  snack,  an evening  meal,  and 
an optional evening snack will be provided at a similar clock time to the clock 
time when these meals are provided relative to dosing on Day 1 while inpatient 
ie, approximately 0H, 4H, 6H (optional snack), 10H, and 14H (optional snack).  
• The total daily  nutritional composition should be approximately  
55% carbohydrate, 30% fat and 15% protein. The nutritional macronutrient 
composition  consumed  by each participant  should  be maintained,  as much  as 
practically possible.  
• The daily  caloric  intake  per participant  should  not exceed  approximately 
3200 kcal.  
• Participants  will refrain  from  consuming  red wine,  grapefruit,  or 
grapefruit -related  citrus  fruits  (eg, Seville  oranges,  pomelos,  fruit juices)  from 
7 days prior to Day 1 and until collection of the final PK blood sample.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  38  
 • When  a meal  or snack  is scheduled  at the same  time as an ECG  and/or  vital sign 
assessments, the meal will be provided after the ECG and/or vital sign 
assessments are completed.  
5.3.3.  Caffeine,  Alcohol,  and Tobacco  
• Participants will abstain from alcohol for ≥24 hours prior to admission for inpatient 
stay (and for red wine abstain for at least 7 days prior to Day  1), plus have a negative 
breath  alcohol  test on Day -1, and continue  abstaining  from  alcohol  until collection  of 
the final PK blood sample.  
• Participants  will undergo  breath  alcohol  tests at timepoints  indicated  in the SoA, 
additional tests may be conducted at investigator discretion  
• Consumption  of caffeinated  drinks  and tobacco  (or nicotine  containing  products)  is 
permitted during participation in the study; however, there may  be a need for brief 
interruption while at the site, depending on local site policy.  
In addition:  
• Participants  must  abstain  from  caffeine -containing  products  for a minimum  of 2 hours 
prior to all vital signs and ECG measurements conducted throughout study 
participation (from screening to the final follow -up visit).  
• Smoking may  not be permitted when it would interfere with the timing of scheduled 
study procedures. In addition, participants must abstain from use of tobacco - or 
nicotine -containing products: for a minimum of 2 hours prior to all vital signs and 
ECG  measurements;  for a minimum  of 2 hours  prior  to and following  administration 
of study intervention.  
5.3.4.  Activity  
• Participants will not be permitted to engage in physically strenuous exercise (eg, 
heavy  lifting,  weight  training,  calisthenics,  and aerobics)  within  48 hours  before  each 
blood sample collection for clinical laboratory tests while participating in the study; 
physical activity at an individual participant’s normal pace is permitted.  
• In order  to standardize  the conditions  on PK sampling  days,  all participants  will be 
required to refrain from lying down (except if required for study procedures,  
eg, ECG),  eating,  and drinking  beverages  other  than water  during  the first 4 hours 
after dosing.  
5.4. Screen  Failures  
Screen  failures  are defined  as participants  who consent  to participate  in the clinical  study  but 
are not subsequently enrolled in the study. Screen failure data are collected and remain as 
source and are not reported on the CRF.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  39  
 In this study, participants may be rescreened only after contact with a sponsor Clinical 
representative. This may be permitted when, for example due to logistical constraints or 
administrative reasons, the maximum period between screening visit and Day  1, of 28 days, 
is exceeded.  In addition,  for participants  in Groups  2-4 only, rescreening  may be appropriate 
following mild intercurrent illness after the condition has resolved. Otherwise, individuals 
who do not meet the criteria for participation in this study (screen failure) may not be 
rescreened.  
In cases where rescreening is permitted, all screening procedures must be repeated and the 
participant  assigned  a new 8-digit SSID  number.  Participants  must  be deemed  to meet  all the 
eligibility criteria under the new 8 -digit SSID before  progressing to Day 1. Reconsent is 
required.  
6. STUDY  INTERVENTION(S)  AND  CONCOMITANT  THERAPY  
Study  interventions  are all prespecified  investigational  products,  medical  devices,  and other 
interventions (eg, surgical and behavioral) intended to be administered to the study 
participants during the study conduct.  
For the purposes  of this protocol,  study  intervention  refers  to PF-07081532.  
6.1. Study  Intervention(s)  Administered  
 
Study  Intervention(s)  
Intervention  Name  PF-07081532  
Arm  Name  
(group of participants receiving a 
specific  treatment  or no treatment)  Group  1, Group  2, Group  3, Group  4 
Type  Drug  
Dose  Formulation  Tablet  
Unit  Dose  Strength(s)  20 mg 
Dosage  Level(s)  20 mg, single dose 
Route  of Administration  Oral 
Use Experimental  
IMP or NIMP/AxMP  IMP 
Sourcing  Provided  centrally by  the sponsor. Refer  to the IPM.  
Packaging  and Labeling  Study  intervention  will be provided  as open -label  supply  in bulk bottles 
along with individual dose containers, as necessary, for unit dosing.  
Current/Former  Name(s)  or Alias(es)  PF-07081532  20 mg tablets  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  40  
  
Study  Arm(s)  
Arm  Title  Group  1 Group  2 Group  3 Group  4 
Arm  Type  Experimental  Experimental  Experimental  Experimental  
Arm 
Description  Participants 
without hepatic 
impairment  will 
receive a single 
20 mg dose of 
PF-07081532,  
administered  orally 
as 1 PF -07081532  
20 mg tablet  Participants  with 
mild hepatic 
impairment will 
receive a single 
20 mg dose of 
PF-07081532,  
administered  orally 
as 1 PF -07081532  
20 mg tablet  Participants  with 
moderate  hepatic 
impairment will 
receive a single 
20 mg dose of 
PF-07081532,  
administered  orally 
as 1 PF -07081532  
20 mg tablet  Participants  with 
severe hepatic 
impairment will 
receive a single 
20 mg dose of 
PF-07081532,  
administered  orally 
as 1 PF -07081532  
20 mg tablet  
Associated 
Intervention 
Labels  PF-07081532  PF-07081532  PF-07081532  PF-07081532  
PF-07081532 will be supplied by Pfizer as 20 mg tablets in open -label bulk bottles along 
with individual dosing containers, as necessary, for unit dosing. For the 20 mg dose 
administered  in this study,  participants  will take 1 PF-07081532  20-mg tablet,  orally,  with 
the morning meal as described in Section 5.3.2 . 
6.1.1.  Administration  
Following an overnight fast of at least  8 hours, participants will receive breakfast as outlined 
in Section 5.3.2  (Meals and Dietary Restrictions). The participants will then receive study 
intervention  at approximately  08:00  hours  (plus  or minus  2 hours)  on Day 1. Investigator  site 
personnel will administer study intervention with ambient temperature water to a total 
volume of approximately 120 mL . Participants will swallow the study intervention whole, 
and will not manipulate or chew the study intervention prior to swallowing.  
6.2. Preparation,  Handling,  Storage,  and Accountability  
1. The investigator  or designee  must  confirm  that appropriate  conditions  
(eg, temperature) have been maintained during transit for all study  interventions 
received  and any discrepancies  are reported  and resolved  before  use of the study 
intervention.  
2. Only  participants  enrolled  in the study  may receive  study  intervention  and only 
authorized site staff may  supply, prepare, and/or administer study  intervention.  
3. All study interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated recording) area in accordance with the labeled 
storage  conditions  with access  limited  to the investigator  and authorized  site staff.  At 
a minimum,  daily  minimum  and maximum  temperatures  for all site storage  locations 
must be documented and available upon request. Data for nonworking days must  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  41  
 indicate  the minimum  and maximum  temperatures  since  previously  documented  upon 
return to business.  
4. Any excursions from the study intervention label storage conditions should be 
reported to Pfizer upon discovery  along with actions taken. The site should actively 
pursue  options  for returning  the study  intervention  to the labeled  storage  conditions, 
as soon as possible. Once an excursion is identified, the study intervention must be 
quarantined and not used until Pfizer provides permission to use the study 
intervention. Specific details regarding the excursion definition and information to 
report for each excursion will be provided to the site in the IPM.  
5. Any storage  conditions  stated  in the SRSD  will be superseded  by the storage 
conditions stated on the label.  
6. Study  interventions  should  be stored  in their original  containers.  
7. The investigator,  institution,  head  of the medical  institution  (where  applicable),  or 
authorized site staff is responsible for study intervention accountability, 
reconciliation, and record maintenance (ie, receipt, reconciliation, and final 
disposition records), such as the IPAL or sponsor -approved equivalent. All study 
interventions will be accounted for using a study intervention accountability 
form/record.  
8. Further guidance and information for the final disposition of unused study 
interventions are provided in the IPM. All destruction must be adequately 
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroyed in compliance with 
applicable  environmental  regulations,  institutional  policy,  and any special  instructions 
provided by Pfizer.  
Upon  identification  of a product  complaint,  notify  the sponsor  within  1 business  day of 
discovery as described in the IPM.  
6.2.1.  Preparation  and Dispensing  
Within  this protocol,  preparation  refers  to the investigator  site activities  performed  to make 
the study  intervention ready  for administration or dispensing to the participant by  qualified 
staff. Dispensing is defined as the provision of study  intervention, concomitant treatments, 
and accompanying information by qualified staff member(s) to a healthcare provider, 
participant, in accordance with this protocol. Local health authority regulations or 
investigator site guidelines may use alternative terms for these activities.  
Tablets will be prepared at the CRU in the individual dosing containers by 2 operators, 1 of 
whom  is an appropriately  qualified  and experienced  member  of the study  staff (eg, physician, 
nurse,  physician’s  assistant,  nurse  practitioner,  pharmacy  assistant/technician,  or pharmacist). 
The tablets will be provided in unit dose containers and labeled in accordance with Pfizer 
regulations and the clinical site’s labeling requirements.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  42  
 6.3. Assignment  to Study  Intervention  
This is an open -label study in which each participant dosed will receive a single 20 mg dose 
of PF -07081532. Following completion of informed consent at the screening visit, each 
participant  will be assigned  a single  8 digit SSID  number  by the site staff.  The first 4 digits  of 
the SSID will reflect the sponsor -assigned site number and the remaining 4 digits will reflect 
each participant’s unique number assigned in chronological order of when informed consent 
is obtained. Each participant who is dosed with study intervention will also be assigned a 
separate, distinct number (as provided to the site by the sponsor), to enable execution of the 
sponsor’s standard processes for analysis of PK samples.  
6.4. Blinding  
This is an open -label  study.  
6.4.1.  Blinding  of Participants  
Participants  will be unblinded  to their assigned  study  intervention.  
6.4.2.  Blinding of Site Personnel  
Investigators  and other  site staff will be unblinded  to participants’  assigned  study 
intervention.  
6.4.3.  Blinding of the Sponsor  
Sponsor  staff will be unblinded  to participants’  assigned  study  intervention.  
6.5. Study  Intervention  Compliance  
When  the individual  dose for a participant  is prepared  from  a bulk supply,  the preparation  of 
the dose will be confirmed by a second qualified member of the study site staff.  
When  participants  are dosed  at the site, they will receive  study  intervention  directly  from  the 
investigator or designee, under medical supervision. The date and time of each dose 
administered  in the clinic  will be recorded  in the source  documents  and recorded  in the CRF. 
The dose of study intervention and study participant identification will be confirmed at the 
time of dosing by a member of the study site staff other than the person administering the 
study  intervention.  Study  site personnel  will examine  each participant’s  mouth  to ensure  that 
the study intervention was ingested.  
A record of the number of study intervention tablets dispensed to and taken by each 
participant  must  be maintained  and reconciled  with study  intervention  and compliance 
records.  
6.6. Dose  Modification  
Dose  modification  of PF-07081532  is not allowed.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  43  
 6.7. Continued  Access  to Study Intervention  After  the End of the Study  
No study  intervention will be provided to participants at the end of their study  participation.  
6.8. Treatment  of Overdose  
For this study, any  dose of PF-07081532 greater  than CCI  within  a 24-hour time period  will 
be considered an overdose. This dose is projected to result in exposure that will exceed that 
observed at the NOAEL in the pivotal 9 -month toxicology study in monkeys, after 
accounting for species differences in plasma protein binding.  
There  is no specific treatment  for an overdose.  
In the event  of an overdose,  the investigator/treating  physician  should:  
1. Contact  the study  medical monitor within 24 hours.  
2. Closely  monitor  the participant  for any AEs/SAEs  and laboratory  abnormalities  as 
medically appropriate and at least until the next scheduled follow -up. 
3. Document  the quantity  of the excess  dose as well as the duration  of the overdose  in 
the CRF.  
4. Overdose  is reportable  to Pfizer  Safety  only when  associated  with  an SAE.  
5. Obtain  a blood  sample  for PK analysis  within  3 days from  the date of the last dose of 
study intervention if requested by the study medical monitor (determined on a  
case-by-case basis).  
6.9. Prior  and Concomitant  Therapy  
All concomitant  treatments  taken  during  the study  must  be recorded  with indication,  daily 
dose, and start and stop dates of administration. All participants will be questioned about 
concomitant treatment at each clinic visit.  
Treatments taken within 28 days before study intervention dosing on Day 1 will be 
documented  as a prior  treatment.  Treatments  taken  after the first dose of study  intervention 
will be documented as concomitant treatments.  
Females using hormonal contraceptives or taking hormone replacement therapy are eligible 
to participate  in this study.  See Appendix  4 for hormonal  contraceptives  that are permitted  in 
this study.  
Participants on certain medications are excluded from the study (see CCI  for list of 
prohibited medications CCI  and Appendix  10 for a list of 
other prohibited medications.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  44  
 
CCI Sites  are encouraged  to contact  the sponsor  should  there  be questions  as to whether  a 
medication is permitted or prohibited.  
6.9.1.  Participants  in Group  1 Only  (without  Hepatic  Impairment)  
In general,  participants  in Group  1 (without  hepatic  impairment)  will abstain  from  all 
concomitant treatments, except for the treatment of AEs. Of note, are the following 
restrictions:  
• Acetaminophen/paracetamol may  be used at doses of ≤1 g/day;  
• Herbal  supplements  must  be discontinued  at least  28 days prior  to Day 1 and until the 
follow -up contact;  
• Limited use of prescription and nonprescription medications  that are not believed to 
affect  the overall  results  of the study  may be permitted  on a case-by-case basis  after  
approval  from the sponsor study team.  
6.9.2.  Participants  in Groups  2, 3 & 4 Only  (Hepatic  Impairment)  
Participants in Groups 2, 3 & 4 (with hepatic impairment) are permitted to be on stable doses 
of background medications  for the management of their concomitant medical condition(s), as 
long as this is in line with protocol specifications regarding prohibited medications as 
described  above  in Section  6.9 and in Appendix  9 and Appendix  10. On a case-by-case basis, 
with approval from the sponsor, participants receiving fluctuating concomitant 
medication/treatment  may be considered  if the underlying  disease  is under  control.  Whenever  
possible , attempts must be made to not add new medications or alter the doses and regimens 
of the concomitant medications after enrollment and for the duration of participation in this 
study, except in circumstances where a change is deemed medically necessary. Any changes 
must be captured in the CRF.  
Participants  may receive  any permitted  background  medications  according  to their stable 
medication routine at their usual dosing times. This is with the exception of  
which must 
not be administered  within  the 8 hours  before  study  intervention  dosing  or within  the 4 hours 
after study intervention dosing on Day 1. On Day 1 , the investigator will determine the 
appropriate time to administer medications that are to be taken on an empty stomach.  
Otherwise, permitted concomitant medications that may be administered under fed 
conditions  can be taken  with breakfast  on the morning  of Day 1. On all other  study  days, 
participants are to receive their background medications at their usual times.  
6.9.3.  Rescue Medicine  
There  is no rescue  therapy  to reverse  AEs observed  with PF-07081532;  standard  medical 
supportive care must be provided to manage any AEs.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  45  
 7. DISCONTINUATION  OF STUDY  INTERVENTION  AND  PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
7.1. Discontinuation  of Study  Intervention  
Since  this is a single -dose study,  this section  is not applicable.  
7.2. Participant  Discontinuation/Withdrawal  From  the Study  
A participant  may withdraw  from  the study  at any time at their own request.  Reasons  for 
discontinuation from the study include the following: safety, behavioral, compliance or 
administrative reasons, or if the study is terminated by sponsor.  
At the time of discontinuing  from  the study,  if possible,  an early  discontinuation  visit should 
be conducted. See the SoA for assessments to be collected at the time of study 
discontinuation and follow -up and for any further evaluations that need to be completed.  
The early  discontinuation visit applies only  to participants who are enrolled and  then are 
prematurely  withdrawn  from  the study.  Participants  should  be questioned  regarding  their 
reason for withdrawal. The participant will be permanently discontinued from the study 
intervention and the study at that time.  
If a participant withdraws from the study, they may request destruction of any remaining 
samples  taken  and not tested,  and the investigator  must  document  any such requests  in the 
site study records and notify the sponsor accordingly.  
If the participant  withdraws  from  the study  and also withdraws  consent  (see Section  7.2.1 ) 
for disclosure of future information, no further evaluations will be performed and no 
additional data will be collected. The sponsor may retain and continue to use any data 
collected before such withdrawal of consent.  
7.2.1.  Withdrawal of  Consent  
Participants  who request  to discontinue  receipt  of study  intervention  will remain  in the study 
and must continue to be followed for protocol -specified follow -up procedures. The only 
exception  to this is when  a participant  specifically  withdraws  consent  for any further  contact 
with them or persons previously authorized by the participant to provide this information.  
Participants should notify the investigator in writing of the decision to withdraw consent 
from future follow -up, whenever possible. The withdrawal of consent should be explained in 
detail in the medical records by the investigator, as to whether the withdrawal is only from 
further  receipt  of study  intervention  or also from  study  procedures  and/or  posttreatment  study 
follow -up, and entered on the appropriate CRF page. In the event that vital status (whether 
the participant is alive or dead) is being measured, publicly available information should be 
used to determine vital status only as appropriately directed in accordance with local law.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  46  
 7.3. Lost  to Follow -up 
A participant  will be considered  lost to follow -up if the participant  repeatedly  fails to return 
for scheduled visits and is unable to be contacted by the study site.  
The following  actions  must  be taken  if a participant  fails to attend  a required  study  visit:  
• The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible. Counsel the participant on the importance of maintaining the 
assigned  visit schedule  and ascertain  whether  the participant  wishes  to and/or  should 
continue in the study;  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make  every  effort  to regain  contact  with the participant  (where  possible,  3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address  or local equivalent methods). These contact attempts  should be documented 
in the participant’s medical record;  
• Should  the participant  continue  to be unreachable,  the participant  will be considered 
to have withdrawn from the study.  
8. STUDY ASSESSMENTS AND  PROCEDURES  
8.1. Administrative  Procedures  
The investigator  (or an appropriate  delegate  at the investigator  site) must  obtain  a signed  and 
dated ICD before performing any study -specific procedures.  
Study  procedures  and their timing  are summarized  in the SoA. Protocol  waivers  or 
exemptions are not allowed.  
Adherence  to the study  design  requirements,  including  those  specified  in the SoA, is essential 
and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that potential 
participants  meet  all eligibility  criteria.  The investigator  will maintain  a screening  log to 
record  details  of all participants  screened  and to confirm  eligibility  or record  reasons  for 
screening failure, as applicable.  
Participants  will be screened  within  28 days prior  to administration  of the study  intervention 
to confirm that they meet the study population criteria for the study. If the time between 
screening and dosing exceeds 28 days as a result of unexpected delays (eg, delayed drug 
shipment), then participants may be rescreened after contact with a sponsor Clinical 
representative as described in Section 5.4 . 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  47  
 Every effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may be 
circumstances outside the control of the investigator that make it unfeasible to perform the 
test. In these cases, the investigator must take all steps necessary to ensure the safety and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator  will document  the reason  for the missed  test and any corrective  and preventive 
actions that they have taken to ensure that required processes are adhered to as soon as 
possible. The study team must be informed of these incidents in a timely manner.  
If done  around  the time of a blood  draw,  ECGs  and vital sign assessments  (BP and pulse  rate) 
should be collected before the blood draw.  If an IV catheter is utilized for blood sample 
collections, ECGs and vital sign assessments (BP and pulse rate) should be collected before 
insertion of the catheter.  
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment  instructions  and contact  information  will be provided  to the investigator  site prior 
to initiation of the study.  
The total blood sampling volume for individual participants in this study is approximately 
170 mL. The actual collection times of blood sampling may change. Additional blood 
samples may  be taken for safety assessments at times specified by Pfizer, provided the total 
volume  taken  during  the study  does not exceed  550 mL during  any period  of 56 consecutive 
days.  
To prepare  for study  participation,  participants  will be instructed  on the information  in the 
Lifestyle Considerations  and Concomitant Therapy  sections of the protocol.  
8.2. Efficacy  Assessments  
Not applicable.  
8.3. Safety  Assessments  
Planned  time points  for all safety  assessments  are provided  in the SoA. Unscheduled  safety 
measurements may  be obtained at any  time during the study  to assess any  perceived safety 
issues.  
8.3.1.  Physical Examinations  
A complete  physical  examination  will include,  at a minimum,  head,  ears, eyes,  nose,  mouth, 
neck,  skin,  heart  and lung examinations,  lymph  nodes,  and gastrointestinal,  musculoskeletal, 
and neurological systems.  
A brief  physical  examination  will include,  at a minimum,  assessments  of general  appearance, 
the respiratory and cardiovascular systems, and participant -reported symptoms.  
Physical  examinations  may be conducted  by a physician,  trained  physician’s  assistant,  or 
nurse practitioner as acceptable according to local regulation.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  48  
 Height and weight will also be measured per the SoA and recorded in the CRF. For 
measuring weight, a scale with appropriate range and resolution is used and must be placed 
on a stable,  flat surface.  Participants  must  remove  shoes,  bulky  layers  of clothing,  and jackets 
so that only light clothing remains. They must also remove the contents of their pockets and 
remain still during measurement of weight.  
Physical  examination  findings  collected  during  the study  will be considered  source  data and 
will not be required to be reported, unless otherwise noted. Any untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.4.1  to 8.4.3 . 
8.3.2.  Vital Signs  
8.3.2.1.  Blood  Pressure  and Pulse  Rate  
Blood  pressure  and pulse  rate will be measured  as defined  in the SoA. 
• Single, seated  BP and pulse rate will be measured with the participant’s arm 
supported  at the level  of the heart,  and recorded  to the nearest  mmHg,  following  a rest 
of ≥5 minutes ; 
• Same  arm (preferably  the dominant  arm)  will be used for BP/pulse  rate assessment 
throughout the study;  
• BP/pulse  rate assessment  should  not be taken  from  the arm with an IV catheter,  if 
placed;  
• Participants  should  be instructed  not to speak  during  BP/pulse  rate measurements.  
The same  properly  sized  and calibrated  BP cuff will be used to measure  BP each time.  The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manually, pulse rate will be measured in the brachial/radial artery for at least  
30 seconds.  When  the timing  of these  measurements  coincides  with a blood  collection,  BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.  
Additional  collection  times,  or changes  to collection  times,  of BP and pulse  rate will be 
permitted, as necessary, to ensure appropriate collection of safety data.  
Any untoward  vital sign findings  that are identified  during  the active  collection  period  and 
meet the definition of an  AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Section 8.4.1  to 8.4.3 . 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  49  
 8.3.3.  Electrocardiograms  
Supine  standard  12-lead ECGs  utilizing  limb leads  (with  a 10-second  rhythm  strip)  should  be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically calculates the HR and measures PR interval, QT interval, QTcF, and QRS 
complex. Alternative lead placement methodology using torso leads (eg, Mason -Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant 
has rested quietly for at least 5 minutes in a supine position.  
To ensure  safety  of the participants,  a qualified  individual  at the investigator  site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
postdose QTcF interval is increased by  ≥60 ms from the baseline and is >450 ms; or b) an 
absolute QT value is ≥500 ms for any scheduled ECG. If either of these conditions occurs, 
then 2 additional  ECGs  will be collected  approximately  2 to 4 minutes  apart  to confirm  the 
original measurement. If the QTcF values from these repeated ECGs remain above the 
threshold value, then a single ECG must be repeated at least hourly until QTc values from 
2 successive ECGs fall below the threshold value that triggered the repeat measurement.  
If a) a postdose QTcF interval remains ≥60 ms from the baseline and is >450 ms; or b) an 
absolute  QT value  is ≥500  ms for any scheduled  ECG  for greater  than 4 hours  (or sooner,  at 
the discretion  of the investigator);  or c) QTcF  value  get progressively  longer,  the participant 
should undergo continuous ECG monitoring. A cardiologist should be consulted if QTcF 
values do not return to less than the criteria listed above after 8 hours of monitoring (or 
sooner, at the discretion of the investigator).  
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as  contributing to the ECG  abnormality. It is  important that leads  be placed  in the 
same  positions  each time in order  to achieve  precise  ECG  recordings.  If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may not be necessary if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.  
ECG  values  of potential  clinical  concern  are listed  in Appendix 8. 
8.3.4.  Clinical  Safety  Laboratory  Assessments  
See Appendix  2 for the list of clinical  safety  laboratory  tests to be performed  and the SoA for 
the timing and frequency. All protocol -required laboratory assessments, as defined in 
Appendix 2 , must be conducted in accordance with the laboratory manual and the SoA. 
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study 
to assess any perceived safety issues.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  50  
 The investigator must review the laboratory report, document this review, and record any 
clinically significant changes occurring during the study in the AE section of the CRF. 
Clinically  significant abnormal laboratory  test findings are those that are not associated with 
the underlying  disease,  unless  judged  by the investigator  to be more  severe  than expected  for 
the participant’s condition.  
All laboratory tests with values considered clinically significant and abnormal during 
participation  in the study  or within  5 days after  the last dose of study  intervention  should  be 
repeated until the values return to normal or baseline or are no longer considered clinically 
significant by the investigator or study medical monitor.  
If such values  do not return  to normal/baseline  within  a period  of time judged  reasonable  by 
the investigator, the etiology should be identified and the sponsor notified.  
See Appendix  6 for suggested  actions  and follow -up assessments  in the event  of potential 
DILI.  
See Appendix  7 for instructions  for laboratory  testing  to monitor  kidney  function  and 
reporting laboratory test abnormalities.  
8.3.5.  Management  of Hypoglycemia  
While  GLP -1R agonists  typically  are not associated  with hypoglycemia  unless  
co-administered with anti -diabetic agents that can cause hypoglycemia (such as insulin or 
sulfonylureas), participants will be monitored for signs and symptoms of hypoglycemia. 
Blood  glucose  concentrations  may be measured  via a glucometer,  at investigator  discretion.  
Any episode  of hypoglycemia  must  be captured  on the AE CRF  with specific  details  captured 
on the HAE Form CRF. For the definition of a hypoglycemic episode and severity 
categorization see Section 8.3.5.1 below.  
8.3.5.1.  Definition  and Severity  of Hypoglycemic  Adverse  Event  (HAE)  
The investigator  must  assess  any glucose  values,  if measured,  as well as any signs  or 
symptoms reported by the study participant.  
HAE  is defined as  one of the following:12 
a. Asymptomatic hypoglycemia: An event not accompanied by typical symptoms of 
HAE but a glucose value of <70 mg/dL (3.9 mmol/L) using either glucometer 
(fingerstick  blood  glucose)  at the study  site or sponsor  approved  laboratory  (plasma 
glucose).  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  51  
 b. Documented symptomatic hypoglycemia: An event during which typical symptoms 
of HAE are accompanied with a glucose value of <70 mg/dL (3.9 mmol/L), using 
glucometer (fingerstick blood glucose) at the study site or sponsor approved 
laboratory  (plasma  glucose),  and the clinical  picture  includes  prompt  resolution  with 
food intake, subcutaneous glucagon, or IV glucose.  
c. Probable symptomatic hypoglycemia: An event during which symptoms of HAE are 
not accompanied  by a glucose  determination  but was presumably  caused  by a glucose 
concentration of <70 mg/dL (3.9 mmol/L), and the clinical picture includes prompt 
resolution with food intake, subcutaneous glucagon, or IV glucose.  
Each  episode  of HAE  must  be categorized  with respect  to severity.  In order  to characterize 
the event as severe, all 3 criteria below must be met:  
1. The participant  was unable  to treat him/herself.  Neurologic  impairment,  and not the 
age of the participant, is the explanation for why the participant could not treat 
him/herself and required the assistance of another person.  
2. The participant  exhibited  at least 1 of the following  neurological  symptoms:  
• Memory  loss; 
• Confusion;  
• Uncontrolled  behavior;  
• Irrational  behavior;  
• Unusual difficulty  in awakening;  
• Suspected  seizure;  
• Seizure;  
• Loss  of consciousness.  
3. Either:  
• If blood  glucose  was measured  and was ≤54 mg/dL  (2.7 mmol/L)  using 
glucometer (or laboratory); or  
• If blood  glucose  was not measured,  the clinical  manifestations  were  reversed  by 
oral carbohydrates, subcutaneous glucagon, or IV glucose.  
Events  that do not meet  all the criteria  above  for severe  HAE  are characterized  as mild or 
moderate in severity.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  52  
 8.3.6.  COVID -19 Specific  Assessments  
Assessment of risk for, symptoms of or testing for COVID -19 may be performed at 
screening,  admission  to the CRU  and/or  at other  times  during  the study  at investigator 
discretion and according to local site policies.  
8.3.7.  Pregnancy  Testing  
A serum  pregnancy  test is required  in all females  at screening.  Following  screening, 
pregnancy tests may be urine or serum tests, and must have a sensitivity of at least  
25 mIU/mL.  Pregnancy  tests will be performed  in WOCBP  at the times  listed  in the SoA. In 
WOCBP, following a negative pregnancy  test result at screening, appropriate contraception 
must be commenced or continued and a second negative pregnancy test result will be 
required at Day -1 prior to the participant’s receiving the study intervention on Day 1.  
Pregnancy tests will also be done whenever 1 menstrual cycle is missed during the active 
treatment period (or when potential pregnancy is otherwise suspected) and at the end of the 
study. Pregnancy tests may also be repeated if requested by IRBs/ECs or if required by local 
regulations.  If a urine  test cannot  be confirmed  as negative  (eg, an ambiguous  result),  a serum 
pregnancy test is required. In such cases, the participant must be excluded if the serum 
pregnancy result is positive.  
8.4. Adverse  Events,  Serious  Adverse  Events,  and Other  Safety  Reporting  
The definitions  of an AE and  an SAE  can be found  in Appendix 3. 
AEs may arise from symptoms or other complaints reported to the investigator by the 
participant (or, when appropriate, by a caregiver, surrogate, or the participant’s legally 
authorized  representative),  or they may arise  from  clinical  findings  of the investigator  or 
other healthcare providers (clinical signs, test results, etc).  
The investigator  and any qualified  designees  are responsible  for detecting,  documenting,  and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study (see Section 7.2 ). 
During  the active  collection  period  as described  in Section  8.4.1 , each participant  will be 
questioned about the occurrence of AEs in a nonleading manner.  
In addition,  the investigator  may be requested  by Pfizer  Safety  to obtain  specific  follow -up 
information in an expedited fashion.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  53  
 8.4.1.  Time  Period  and Frequency  for Collecting  AE and SAE  Information  
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”)  for each participant  begins  from  the time the participant  provides  informed  consent, 
which is obtained before undergoing any study -related procedure and/or receiving study 
intervention), through and including a minimum of 28 calendar days, except as indicated 
below, after the last administration of the study intervention.  
Follow -up by the investigator  continues  throughout  the active  collection  period  and until the 
AE or SAE or its sequelae resolve or stabilize at a level acceptable to the investigator.  
When  a clinically  important  AE remains  ongoing  at the end of the active  collection  period, 
follow -up by the investigator continues until the AE or SAE or its sequelae resolve or 
stabilize at a level acceptable to the investigator and Pfizer concurs with that assessment.  
For participants  who are screen  failures,  the active  collection  period  ends when  screen  failure 
status is determined.  
If the participant  withdraws  from  the study  and also withdraws  consent  for the collection  of 
future information, the active collection period ends when consent is withdrawn.  
If a participant  permanently  discontinues  or temporarily  discontinues  study  because  of an AE 
or SAE, the AE or SAE must be recorded on the CRF and the SAE reported using the CT 
SAE Report Form.  
Investigators are not obligated to actively seek information on AEs or SAEs after the 
participant  has concluded  study  participation.  However,  if the investigator  learns  of any SAE, 
including a death, at any time after a participant has completed the study, and they consider 
the event to be reasonably related to the study intervention, the investigator must promptly 
report the SAE to Pfizer using the CT SAE Report Form.  
8.4.1.1.  Reporting  SAEs  to Pfizer Safety  
All SAEs occurring in a participant during the active collection period as described in 
Section  8.4.1  are reported  to Pfizer  Safety  on the CT SAE  Report  Form  immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3 . The investigator will submit any updated SAE data to the sponsor within  
24 hours  of its being  available.  
8.4.1.2.  Recording  Nonserious  AEs and SAEs  on the CRF  
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which  begins  after obtaining  informed  consent  as described  in Section  8.4.1 , will be recorded 
on the AE section of the CRF.  
The investigator  is to record  on the CRF  all directly  observed  and all spontaneously  reported 
AEs and SAEs reported by the participant.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  54  
 As part of ongoing safety reviews conducted by the sponsor, any nonserious AE that is 
determined  by the sponsor  to be serious  will be reported  by the sponsor  as an SAE.  To assist 
in the determination of case seriousness, further information may be requested from the 
investigator to provide clarity and understanding of the event in the context of the clinical 
study.  
Reporting  of AEs and SAEs  for participants  who fail screening  are subject  to the CRF 
requirements as described in Section 5.4 . 
8.4.2.  Method  of Detecting  AEs and SAEs  
The method  of recording,  evaluating,  and assessing  causality  of AEs and SAEs  and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 . 
Care  will be taken  not to introduce  bias when  detecting  AEs and/or  SAEs.  Open -ended  and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.  
8.4.3.  Follow -Up of AEs and SAEs  
After the initial AE or SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain  adequate  information  until resolution,  stabilization,  the event  is otherwise  explained, 
or the participant is lost to follow -up (as defined in Section 7.3 ). 
In general,  follow -up information  will include  a description  of the event  in sufficient  detail  to 
allow for a complete medical assessment of the case and independent determination of 
possible causality. Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary of available 
autopsy findings must be submitted as soon as possible to Pfizer Safety.  
Further  information  on follow -up procedures  is provided  in Appendix 3. 
8.4.4.  Regulatory  Reporting  Requirements  for SAEs  
Prompt notification by the investigator to the sponsor of an SAE is essential so that legal 
obligations  and ethical  responsibilities  toward  the safety  of participants  and the safety  of a 
study intervention under clinical investigation are met.  
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies  about  the safety  of a study  intervention  under  clinical  investigation.  The 
sponsor will comply with country -specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRBs/ECs, and investigators.  
Investigator  safety  reports  must  be prepared  for SUSARs  according  to local  regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  55  
 An investigator who receives SUSARs or other specific safety information (eg, summary or 
listing  of SAEs)  from  the sponsor  will review  and then file it along  with the SRSD(s)  for the 
study and will notify the IRB/EC, if appropriate according to local requirements.  
8.4.5.  Environmental  Exposure,  Exposure  During  Pregnancy  or Breastfeeding,  and 
Occupational Exposure  
Environmental exposure, occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact with or exposure to the study intervention. Such exposure 
may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure  include  healthcare  providers,  family  members,  and others  who may be exposed.  An 
environmental exposure may include EDP, EDB, and occupational exposure.  
Any such exposures  to the study  intervention  under  study  are reportable  to Pfizer  Safety 
within 24 hours of investigator awareness.  
8.4.5.1.  Exposure During Pregnancy  
An EDP  occurs  if: 
• A female  participant  is found  to be pregnant  while  receiving  or after discontinuing 
study intervention . 
• A male  participant  who is receiving  or has discontinued  study  intervention 
inseminates a female partner.  
• A female  nonparticipant  is found  to be pregnant  while  being  exposed  or having  been 
exposed to study intervention because of environmental exposure. Below are 
examples of environmental EDP:  
• A female  family  member  or healthcare  provider  reports  that she is pregnant  after 
having been exposed to the study intervention by ingestion.  
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness,  irrespective  of whether  an SAE  has occurred.  The initial  information  submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy).  
• If EDP occurs in a participant/participant’s partner, the investigator must report this 
information  to Pfizer  Safety  on the CT SAE  Report  Form  and an EDP  Supplemental 
Form, regardless of whether an SAE has occurred. Details of the pregnancy will be 
collected after the start of study intervention and until 28 days after the last dose.  
• If EDP  occurs  in the setting  of environmental  exposure,  the investigator  must  report 
information  to Pfizer  Safety  using  the CT SAE  Report  Form  and EDP  Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  56  
 the study,  the information  is not recorded  on a CRF;  however,  a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.  
Follow -up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a 
follow -up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrity  of the neonate  can be assessed  at the time of birth.  In the event  of a termination,  the 
reason(s) for termination should be specified and, if clinically possible, the structural 
integrity of the terminated fetus should be assessed by gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomaly and the findings are 
reported).  
Abnormal  pregnancy  outcomes  are considered  SAEs.  If the outcome  of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomaly [in a live -born baby, a terminated fetus, an 
intrauterine  fetal demise,  or a neonatal  death]),  the investigator  should  follow  the procedures 
for reporting SAEs. Additional information about pregnancy outcomes that are reported to 
Pfizer Safety as SAEs follows:  
• Spontaneous  abortion  including  miscarriage  and missed  abortion  should  be reported 
as an SAE;  
• Neonatal  deaths  that occur  within  1 month  of birth  should  be reported,  without  regard 
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly related to 
exposure to the study intervention.  
Additional information regarding the EDP may be requested by the sponsor. Further 
follow -up of birth outcomes will be handled on a case -by-case basis (eg, follow -up on 
preterm infants to identify developmental delays). In the case of paternal exposure, the 
investigator  will provide  the participant  with the Pregnant  Partner  Release  of Information  
Form to deliver to his partner. The investigator must document in the source documents that 
the participant  was given  the Pregnant  Partner  Release  of Information  Form  to provide  to his 
partner.  
8.4.5.2.  Exposure During Breastfeeding  
An EDB  occurs  if: 
• A female  participant  is found  to be breastfeeding  while  receiving  or after 
discontinuing study intervention.  
• A female  nonparticipant  is found  to be breastfeeding  while  being  exposed  or having 
been exposed to study intervention (ie, environmental exposure). An example of 
environmental EDB is a female family member or healthcare provider who reports  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  57  
 that she is breastfeeding  after having  been  exposed  to the study  intervention  by 
ingestion.  
The investigator must report EDB to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported 
using  the CT SAE  Report  Form.  When  EDB  occurs  in the setting  of environmental  exposure, 
the exposure information does not pertain to the participant enrolled in the study , so the 
information is not recorded on a CRF. However, a copy of the completed CT SAE Report 
Form is maintained in the investigator site file.  
An EDB report is not created when a Pfizer drug specifically approved for use in 
breastfeeding women (eg, vitamins) is administered in accordance with authorized use. 
However,  if the infant  experiences  an SAE  associated  with such a drug,  the SAE  is reported 
together with the EDB.  
8.4.5.3.  Occupational Exposure  
The investigator must report any  instance of occupational exposure to Pfizer Safety within 
24 hours of the investigator’s awareness using the CT SAE Report Form regardless of 
whether  there  is an associated  SAE.  Since  the information  about  the occupational  exposure 
does not pertain to a participant enrolled in the study, the information is not recorded on a 
CRF; however, a copy of the completed CT SAE Report Form must be maintained in the 
investigator site file.  
8.4.6.  Cardiovascular  and Death  Events  
Not applicable.  
8.4.7.  Disease -Related  Events  and/or  Disease -Related  Outcomes  Not Qualifying  as AEs 
or SAEs  
Not applicable.  
8.4.8.  Adverse  Events  of Special  Interest  
Not applicable.  
8.4.8.1.  Lack  of Efficacy  
This section  is not applicable  because  efficacy  is not expected  in the study  population.  
8.4.9.  Medical  Device  Deficiencies  
Not applicable . 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  58  
 8.4.10.  Medication  Errors  
Medication errors may result from the administration or consumption of the study 
intervention  by the wrong  participant,  or at the wrong  time,  or at the wrong  dosage  strength.  
Medication  errors  are recorded  and reported  as follows:  
 
Recorded on the 
Medication  Error  Page 
of the CRF  Recorded on the 
Adverse  Event  Page 
of the CRF  Reported on the CT SAE 
Report Form to Pfizer 
Safety  Within  24 Hours  of 
Awareness  
All (regardless  of whether 
associated with an AE)  Any AE or SAE  associated 
with the medication error  Only  if associated  with an 
SAE 
Medication  errors  include:  
• Medication  errors  involving  participant  exposure  to the study  intervention;  
• Potential  medication  errors  or uses outside  of what  is foreseen  in the protocol  that do 
or do not involve the study participant.  
Such  medication  errors  occurring  to a study  participant  are to be captured  on the medication 
error page of the CRF, which is a specific version of the AE page.  
Whether or not the medication error is accompanied by an AE, as determined by the 
investigator,  the medication  error  is recorded  on the medication  error  page  of the CRF  and, if 
applicable,  any associated  AE(s),  serious  and nonserious,  are recorded  on the AE page  of the 
CRF.  
In the event of a medication dosing error, the sponsor should be  notified  within 24 hours.  
Medication  errors  should  be reported  to Pfizer  Safety  within  24 hours  on a CT SAE  Report 
Form only when associated with an SAE.  
8.5. Pharmacokinetics  
8.5.1.  Plasma  for Analysis  of PF-07081532  
Blood samples of approximately 3 mL, to provide a minimum volume of 1 mL plasma, will 
be collected  into appropriately  labeled  tubes  containing  K2EDTA  for measurement  of plasma 
concentrations of PF -07081532 as specified in the SoA. Instructions for the collection and 
handling of biological samples will be provided in the laboratory manual or by the sponsor. 
The actual date and time (24 -hour clock time) of each sample will be recorded.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  59  
 The actual times may change, but the number of samples will remain the same. All efforts 
will be made  to obtain  the samples  at the exact  nominal  time relative  to dosing.  Collection  of 
samples up to and including 10 hours after dose administration that are obtained within  
10% of the nominal  time relative  to dosing  (eg, within  6 minutes  of a 60-minute  sample)  will 
not be captured  as a protocol  deviation,  as long as the exact  time of the collection  is noted  on 
the source document and the CRF. Collection of samples more than 10 hours after dose 
administration that are obtained ≤1 hour away from the nominal time relative to dosing will 
not be captured  as a protocol  deviation,  as long as the exact  time of the collection  is noted  on 
the source document and the CRF.  
Samples  will be used to evaluate  the PK of PF-07081532.  Samples  collected  for analyses  of 
plasma concentration may also be used to evaluate safety or efficacy aspects related to 
concerns arising during or after the study, for metabolite identification and/or evaluation of 
the bioanalytical method, or for other internal exploratory purposes.  
Genetic  analyses  will not be performed  on these  plasma  samples  unless  consent  for this was 
included in the informed consent. Participant confidentiality will be maintained.  
Samples collected for measurement of plasma concentrations of PF -07081532 will be 
analyzed  using  a validated  analytical  method  in compliance  with applicable  SOPs.  Potential 
metabolites may be analyzed with either validated or exploratory methods.  
The PK samples  must be processed  and shipped  as indicated  in the instructions  provided  to 
the investigator site to maintain sample integrity. Any deviations from the PK sample 
handling  procedure  (eg, sample  collection  and processing  steps,  interim  storage  or shipping 
conditions), including any actions taken, must be documented and reported to the sponsor. 
On a case -by-case basis, the sponsor may make a determination as to whether sample 
integrity has been compromised.  
8.5.2.  Plasma  for Determination  of PF-07081532  Unbound  Fraction  
During the study, blood samples of approximately 10 mL to provide sufficient plasma 
(approximately 4 mL) for unbound fraction determination, will be collected into 
appropriately  labeled tubes containing K 2EDTA, as specified in the SoA. Instructions for the 
collection  and handling  of biological  samples  will be provided  in the laboratory  manual  or by 
the sponsor. The actual date and time (24 -hour clock time) of each sample will be recorded.  
The actual times may change, but the number of samples will remain the same. All efforts 
will be made  to obtain  the samples  at the exact  nominal  time relative  to dosing.  Collection  of 
samples up to and including 10 hours after dose administration that are obtained within  
10% of the nominal  time relative  to dosing  (eg, within  6 minutes  of a 60-minute  sample)  will 
not be captured  as a protocol  deviation,  as long as the exact  time of the collection  is noted  on 
the source document and the CRF.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  60  
 CCI 
CCI Samples  collected  for analyses  of PF-07081532  plasma  protein  binding  may also be used to 
evaluate safety or efficacy aspects related to concerns arising during or after the study, for 
metabolite  identification  and/or  evaluation  of the bioanalytical  method,  or for other  internal 
exploratory purposes.  
Genetic  analyses  will not be performed  on these  plasma  samples  unless  consent  for this was 
included in the informed consent. Participant confidentiality will be maintained.  
Samples  collected  for measurement  of PF-07081532  plasma  protein  binding  will be analyzed 
using a validated analytical method in compliance with applicable SOPs. Potential 
metabolites may be analyzed with either validated or exploratory methods.  
The samples for determination of PF -07081532 plasma protein binding must be processed 
and shipped as indicated in the instructions provided to the investigator site to maintain 
sample  integrity.  Any deviations  from  the sample  handling  procedure  (eg, sample  collection 
and processing steps, interim storage or shipping conditions), including any actions taken, 
must be documented and reported to the sponsor. On a case -by-case basis, the sponsor may 
make a determination as to whether sample integrity has been compromised.  
8.6. Genetics  
8.6.1.  Specified  Genetics  
Specified  genetic  analyses  are not evaluated  in this study.  
 
 
 
 
8.7. Biomarkers  
 
 
8.7.2.  Specified  Gene  Expression  (RNA)  Research  
Specified gene expression (RNA) research is not included in this study.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  61  
 8.7.3.  Specified  Protein  Research  
Specified protein research is not included in this study.  
8.7.4.  Specified  Metabolomic  Research  
Specified metabolomic research is not included in this study.  
8.8. Immunogenicity  Assessments  
Immunogenicity  assessments  are not included  in this study.  
8.9. Health  Economics  
Health  economics/medical  resource  utilization  and health  economics  parameters  are not 
evaluated in this study.  
9. STATISTICAL  CONSIDERATIONS  
Detailed  methodology  for summary  and statistical  analyses  of the data collected  in this study 
is outlined here and further detailed in the SAP, which will be maintained by the sponsor.  
The SAP may modify  what  is outlined  in the protocol  where  appropriate;  however,  any major 
modifications of the primary endpoint definitions or their analyses will also be reflected in a 
protocol amendment.  
9.1. Statistical  Hypotheses  
No formal  statistical  hypothesis testing will be performed in this study.  
9.2. Analysis Sets 
For purposes  of analysis,  the following  analysis  sets are defined:  
 
Participant  Analysis 
Set Description  
Enrolled  “Enrolled” means a participant’s, or their legally authorized 
representative’s, agreement to participate in a clinical study 
following completion of the informed consent process and 
assignment to study intervention. A participant will be 
considered  enrolled  if the informed  consent  is not withdrawn 
prior to participating in any study activity after screening.  
Potential participants who are screened for the purpose of 
determining  eligibility  for the study,  but do not participate  in 
the study, are not considered enrolled, unless otherwise 
specified by the protocol.  
Safety  analysis  set All participants  assigned  to study  intervention  and who take at 
least 1 dose of study intervention.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  62  
  
Participant  Analysis 
Set Description  
PK Concentration  Set The PK concentration  population  is defined  as all participants 
who received  at least 1  dose of  PF-07081532 and in whom at 
least 1 plasma concentration value is reported.  
PK Parameter  Set The PK parameter analysis population is defined as all 
participants  who received  at least 1 dose of PF-07081532  and 
have at least 1 of the PK parameters of interest calculated.  
9.3. Statistical Analyses  
The SAP will be developed and finalized before any analyses are performed and will 
describe  the analyses  and procedures  for accounting  for missing,  unused,  and spurious  data. 
This section is a summary of the planned statistical analyses of the primary and secondary 
endpoints.  
9.3.1.  General Considerations  
Endpoints  will be reported  and analyzed  according  to the hepatic  function  group  that 
participants fall into based upon their Child -Pugh score at screening.  
9.3.1.1.  Analyses  for PK Endpoints  
Natural log -transformed PK parameters will be analyzed using an ANOVA model including 
hepatic function group as fixed effect. Estimates of the adjusted means and of the adjusted 
mean  differences  (Test -Reference)  with their corresponding  90% CIs will be obtained  before 
being exponentiated to provide estimates  of the adjusted geometric means  and of  the ratio of 
adjusted geometric means (Test/Reference).  
9.3.2.  Primary  Endpoint(s)  Analysis  
9.3.2.1.  Definition of Endpoint(s)  
The plasma PK parameters for PF -07081532 following single dose administration will be 
derived from the concentration -time profiles as detailed in Table 3 . Actual PK sampling 
times will be used in the derivation of PK parameters. In the case that actual PK sampling 
times are not available, nominal PK sampling time will be used in the derivation of PK 
parameters.  The fraction  of PF-07081532  unbound  in plasma  (fu) will be determined  by the 
analytical lab and reported for each participant.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  63  
 
CCI  
Table  3. Plasma  PK Parameters   
Parameter  Definition   Method  of Determination  
AUC last Area under the plasma 
concentration -time profile  from   Linear/Log  trapezoidal  method.  
 time zero to the time of the last   
 quantifiable  concentration  (Clast)   
AUC inf* Area  under  the plasma   AUC last + (Clast*/k el), where  Clast* is the predicted  
 concentration -time profile  from  plasma  concentration  at the last quantifiable  time 
 time zero extrapolated  to infinite   point  estimated  from  the log-linear  regression  
 time  analysis.  
Cmax Maximum  plasma  concentration   Observed  directly  from  data. 
 
 
 
 
 
 
 
 
 
 
 
fu Fraction  of unbound  drug in 
plasma  Cu/C  (where  Cu represents  unbound 
concentration and C represents total 
concentration).  
AUC last,u  Unbound  AUC last fu∙AUC last. 
AUC inf,u* Unbound  AUC inf fu∙AUC inf. 
Cmax,u  Unbound  Cmax fu∙C max. 
CCI   
 
* as data permit  
9.3.2.2.  Main  Analytical  Approach  
The effect  of varying  degrees  of hepatic  impairment  on PK parameters  will be assessed  by 
constructing 90% CIs around the estimated difference between each of the Test (hepatic 
impaired) groups and the Reference (without hepatic impairment) group. A one -way 
ANOVA will be used to compare the natural log transformed PF -07081532 AUC inf, Cmax, 
AUC last, fraction unbound (fu), and associated unbound parameters (AUC inf,u, Cmax,u, 
AUC last,u), as data permit, for each of the hepatic impairment groups (Test) to the group 
without hepatic impairment (Reference). Estimates of the adjusted mean differences  
(Test  - Reference),  and corresponding  90% confidence  intervals,  will be obtained  from  the 
model.  These  will be exponentiated  to provide  estimates  of the ratio of adjusted  geometric 
means (Test/Reference) and 90% confidence intervals for the ratios.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  64  
 Individual PF -07081532 concentrations will be listed and summarized descriptively by 
nominal PK sampling time and hepatic function group. Individual participant and summary 
profiles  of the concentration -time data (using  actual  and nominal  times,  respectively)  will be 
plotted by hepatic function group for both total plasma PF -07081532 and unbound  
PF-07081532.  
Box and whisker plots for individual PK parameters (AUC inf, AUC last, Cmax, fu, AUC inf,u, 
AUC last,u  and C max,u) will be constructed by hepatic function group and overlaid with 
geometric means. PK parameters of PF -07081532 will be summarized descriptively by 
hepatic  function  group.  Unbound  fraction  (fu) will be listed  and summarized  descriptively 
by hepatic function group.  
9.3.2.3.  Supplementary  Analyses  
Additional analysis using linear regression may be used to analyze the potential relationship 
between  appropriate  PK parameters  (eg, AUC inf, AUC last, Cmax, fu, AUC inf,u, AUC last,u, Cmax,u) 
and hepatic function (eg, serum albumin concentration, PT or T bili). Plots of PK parameters 
(eg, AUC inf, AUC last, Cmax, fu, AUC inf,u, AUC last,u, Cmax,u) versus hepatic function will be 
constructed, with a regression line and 90% confidence region included. Estimates of the 
slope and intercept, together with a 90% CI, and the coefficient of determination  
(ie, R-squared  and adj-R-squared)  may be obtained  from  the model.  
Additionally,  as an exploratory  analysis,  age and body  weight  may be explored  as additional 
covariat es/factors in the models, as appropriate.  
9.3.3.  Secondary  Endpoint  Analysis  - Safety  Analyses  
All safety  analyses  will be  performed on  the safety  population.  
AEs,  ECGs,  BP, pulse  rate, and safety  laboratory  data will be reviewed  and summarized  on 
an ongoing basis during the study to evaluate the safety of participants. Any clinical 
laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be 
described.  Safety  data will be presented  in tabular  and/or  graphical  format  and summarized 
descriptively, where appropriate.  
Medical history and physical examination and neurological examination information, as 
applicable, collected during the course of the study, will be considered source data and will 
not be required to be reported, unless otherwise noted. However, any untoward findings 
identified on physical and/or neurological examinations conducted during the active 
collection period will be captured as AEs, if those findings meet the definition of an AE. 
Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory 
data, ECGs, and vital signs, will be considered source data, and will not be required to be 
reported, unless otherwise noted. Demographic data collected at screening will be reported. 
COVID -19 specific  assessments  data will be considered  source  data and will not be required 
to be reported.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  65  
 CCI 9.3.3.1.  Electrocardiogram Analyses  
Changes  from  baseline  for the ECG  parameters  HR, QTcF,  PR interval,  and QRS  complex 
will be summarized  by treatment  and time.  The frequency  of uncorrected  QT values  above 
500 ms will be tabulated.  
The number  (%) of participants  with maximum  postdose  QTcF  values  and maximum 
increases from baseline in the following categories will be tabulated by treatment:  
 
Safety QTcF Assessment  
 
Degree  of Prolongation  Mild  (ms) Moderate  (ms) Severe  (ms) 
Absolute  value  >450 -480 >480 -500 >500  
Increase  from  baseline   30-60 >60 
 
 
 
 
9.4. Interim  Analyses  
No formal interim analysis will be conducted for this study. As this is an open -label study, 
the sponsor  may conduct  unblinded  reviews  of the data during  the course  of the study  for the 
purpose of safety assessment, facilitating PK modeling, and/or supporting clinical 
development.  
9.5. Sample Size Determination  
A sample  size of approximately  24 participants  (approximately  6 participants  per group,  with 
varying degrees of hepatic function in each of the 4 groups) has been selected to provide 
sufficient precision to detect a 2 -fold difference in AUC inf between each Test group (with 
hepatic  impairment)  and the Reference group (without hepatic impairment).  Table  4 presents 
the 90% CIs (with 80% coverage probability) for various possible effects on AUC inf. The 
same table would be applicable for possible effects on C max. 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  66  
 Table 4.  Expected  Widths  of the 90%  CIs (with  80%  Coverage  Probability)  for 
Different Possible Estimated Effects  
 
Estimated  Effect  
(Test/Reference)  AUC inf 
Probable  90%  CI Probable  CI Width  
 CCI        
      
      
      
      
These estimates are based on an assumed conservative standard deviation of  CC for 
log eAUC inf (also  applicable  to log eCmax) based  on data from  internal  previousI studies  with 
PF-07081532 administered either as a single dose in the fed/fasted state in healthy 
participants  (C3991001)  or as multiple  doses  in the fed state in participants  with T2DM 
(C3991002).  
Participants  who discontinue  from  the study  before  completing  all assessments  may be 
replaced at the discretion of the investigator and sponsor.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  67  
 10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  CONSIDERATIONS  
10.1. Appendix 1: Regulatory, Ethical, and  Study Oversight Considerations  
10.1.1.  Regulatory  and Ethical  Considerations  
This study  will be conducted in accordance with the protocol and with the following:  
• Consensus  ethical  principles  derived  from  international  guidelines,  including  the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;  
• Applicable  ICH GCP  guidelines;  
• Applicable  laws and regulations,  including  applicable  privacy  laws.  
The protocol,  protocol  amendments,  ICD,  SRSD(s),  and other  relevant documents  
(eg, advertisements)  must  be reviewed  and approved  by the sponsor,  submitted  to an IRB/EC 
by the investigator, and reviewed and approved by the IRB/EC before the study is initiated.  
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes  made  to the study  design,  except  for changes  necessary  to eliminate  an immediate 
hazard to study participants.  
Protocols and any substantial amendments to the protocol will require health authority 
approval  prior  to initiation  except  for changes  necessary  to eliminate  an immediate  hazard  to 
study participants.  
The investigator  will be responsible  for the following:  
• Providing  written  summaries  of the status  of the study  to the IRB/EC  annually  or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/EC;  
• Notifying  the IRB/EC  of SAEs  or other  significant  safety  findings  as required  by 
IRB/EC procedures;  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements  of 21 CFR,  ICH GCP guidelines,  the IRB/EC,  European  regulation 
536/2014  for clinical  studies,  European  Medical  Device  Regulation  2017/745  for 
clinical device research, and all other applicable local regulations.  
10.1.1.1.  Reporting  of Safety  Issues  and Serious  Breaches  of the Protocol  or ICH  GCP  
In the event  of any prohibition  or restriction  imposed  (ie, clinical  hold)  by an applicable 
regulatory authority in any area of the world, or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, Pfizer should be informed immediately.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  68  
 In addition, the investigator will inform Pfizer immediately of any urgent safety measures 
taken  by the investigator  to protect  the study  participants  against  any immediate  hazard,  and 
of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.  
10.1.2.  Financial Disclosure  
Investigators  and subinvestigators  will provide  the sponsor  with sufficient,  accurate  financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators 
are responsible  for providing  information  on financial  interests  during  the course  of the study 
and for 1 year after completion of the study.  
10.1.3.  Informed  Consent  Process  
The investigator or the investigator’s representative will explain the nature of the study, 
including the risks and benefits, to the participant and answer all questions regarding the 
study.  The participant  should  be given  sufficient  time and opportunity  to ask questions  and to 
decide whether or not to participate in the trial.  
Participants must be informed that their participation is voluntary. Participants will be 
required  to sign a statement  of informed  consent  that meets  the requirements  of 21 CFR  50, 
local regulations, ICH guidelines, privacy and data protection requirements, where 
applicable, and the IRB/EC or study center.  
The investigator must ensure that each participant is fully informed about the nature and 
objectives  of the study,  the sharing  of data related  to the study,  and possible  risks  associated 
with participation, including the risks associated with the processing of the participant’s 
personal data.  
The participant  must  be informed  that their personal  study -related  data will be used by the 
sponsor  in accordance  with local  data protection  law. The level  of disclosure  must  also be 
explained to the participant.  
The participant  must  be informed  that their medical  records  may be examined  by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/EC members, and by inspectors from regulatory authorities.  
The investigator  further  must  ensure  that each study  participant  is fully  informed  about  their 
right to access and correct their personal data and to withdraw consent for the processing of 
their personal data.  
The medical record must include a statement that written informed consent was obtained 
before  the participant  was enrolled  in the study  and the date on which  the written  consent  was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  69  
 Participants  must  be reconsented  to the most  current  version  of the IRB/EC -approved ICD(s) 
during their participation in the study as required per local regulations.  
A copy of the ICD(s) must be provided to the participant. 
Participants  who are rescreened  are required  to sign a new ICD.  
10.1.4.  Data  Protection  
All parties  will comply  with all applicable  laws,  including  laws regarding  the implementation 
of organizational and technical measures to ensure protection of participant data.  
Participants’  personal  data will be stored  at the study  site in encrypted  electronic  and/or  paper 
form and will be password protected or secured in a locked room to ensure that only 
authorized study staff have access. The study site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site  will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by law.  
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant  records  or data sets that are transferred  to the sponsor  will contain  the numerical 
code; participant names  will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by this single, participant -specific code. The study site will 
maintain a confidential list of participants who participated in the study, linking each 
participant’s numerical code to their actual identity and medical record ID. In case of data 
transfer,  the sponsor  will protect  the confidentiality  of participants’  personal  data consistent 
with the clinical study agreement and applicable privacy laws.  
Information  technology  systems  used to collect,  process,  and store  study -related  data are 
secured by technical and organizational security measures designed to protect such data 
against accidental or unlawful loss, alteration, or unauthorized disclosure or access.  
The sponsor  maintains  standard  operating  procedures  on how to respond  in the event  of 
unauthorized access, use, or disclosure of sponsor information or systems.  
10.1.5.  Committees  Structure  
A data monitoring  committee  or independent  oversight  committee  will not be utilized.  
10.1.5.1.  Data  Monitoring  Committee  
This study  will not use an E -DMC.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  70  
 10.1.6.  Dissemination of Clinical Study Data  
Pfizer fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov  (ClinicalTrials.gov), the EudraCT/CTIS, and/or 
www.pfizer.com,  and other  public  registries  and websites  in accordance  with applicable  local 
laws/regulations. In addition, Pfizer reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.  
In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and 
complete  manner  and are reported  regardless  of the outcome  of the study  or the country  in 
which the study was conducted.  
www.clinicaltrials.gov  
Pfizer  posts  clinical  trial results  on www.clinicaltrials.gov  for Pfizer -sponsored  interventional 
studies (conducted in patients) that evaluate the safety and/or efficacy of a product,  
regardless of the geographical location in which the study is conducted. These results are 
submitted for posting in accordance with the format and timelines set forth by US law.  
EudraCT/CTIS  
Pfizer  posts  clinical  trial results  on EudraCT/CTIS  for Pfizer -sponsored  interventional  studies 
in accordance with the format and timelines set forth by EU requirements.  
www.pfizer.com  
Pfizer  posts  CSR  synopses  and plain -language  study  results  summaries  on www.pfizer.com  
for Pfizer -sponsored  interventional studies at the same time the  corresponding study  results 
are posted to www.clinicaltrials.gov.  CSR synopses will have personally identifiable 
information anonymized.  
Documents within marketing  applications  
Pfizer  complies  with applicable  local  laws/regulations  to publish  clinical  documents  included 
in marketing applications. Clinical documents include summary documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical 
documents will have personally identifiable information anonymized.  
Data  sharing  
Pfizer provides researchers secure access to participant -level data or full CSRs for the 
purposes  of “bona -fide scientific  research”  that contributes  to the scientific  understanding  of 
the disease, target, or compound class. Pfizer will make data from these trials available  
24 months  after study  completion.  Participant -level  data will be anonymized  in accordance 
with applicable privacy laws and regulations. CSRs will have personally identifiable 
information anonymized.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  71  
 Data  requests  are considered  from  qualified  researchers  with the appropriate  competencies  to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.  
10.1.7.  Data Quality Assurance  
All participant  data relating  to the study  will be recorded  on printed  or electronic  CRF  unless 
transmitted  to the sponsor  or designee  electronically  (eg, laboratory  data).  The investigator  is 
responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the CRF.  
Guidance  on completion  of CRFs  will be provided  in the CRF  Completion  Requirements 
document.  
The investigator  must  ensure  that the CRFs  are securely  stored  at the study  site in encrypted 
electronic and/or paper form and are password -protected or secured in a locked room to 
prevent access by unauthorized third parties.  
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source data documents. This 
verification  may also occur  after study  completion.  It is important  that the investigator(s)  and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.  
Monitoring details describing strategy, including definition of study -critical data items and 
processes  (eg, risk-based  initiatives  in operations  and quality,  such as risk management  and 
mitigation strategies and analytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on -site monitoring), are provided in the data management plan and 
monitoring plan maintained and utilized by the sponsor or designee.  
The sponsor  or designee  is responsible  for the data management  of this study,  including 
quality checking of the data.  
Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained by the investigator for 15 years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the sponsor. No records may be 
transferred to another location or party without written notification to the sponsor. The 
investigator  must  ensure  that the records  continue  to be stored  securely  for as long as they are 
maintained.  
When  participant  data are to be deleted,  the investigator  will ensure  that all copies  of such 
data are promptly and irrevocably deleted from all systems.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  72  
 The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate 
with the sponsor  or its agents  to prepare  the investigator  site for the inspection  and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly resolve any discrepancies that are identified 
between the study data and the participant’s medical records. The investigator will promptly 
provide copies of the inspection findings to the sponsor or its agent. Before response 
submission to the regulatory authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to any such findings.  
10.1.8.  Source  Documents  
Source  documents  provide  evidence  for the existence  of the participant  and substantiate  the 
integrity of the data collected. Source documents are filed at the investigator site.  
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator  may need  to request  previous  medical  records  or transfer  records,  depending  on 
the study. Also, current medical records must be available.  
Definition  of what  constitutes  source  data and its origin  can be found  in the Source 
Document Locator, which is maintained by the sponsor.  
Description  of the use of the computerized  system  is documented  in the Data  Management 
Plan, which is maintained by the sponsor.  
The investigator  must  maintain  accurate  documentation  (source  data)  that supports  the 
information entered in the CRF.  
The sponsor  or designee  will perform  monitoring  to confirm  that data entered  into the CRF 
by authorized  site personnel  are accurate,  complete,  and verifiable  from  source  documents; 
that the safety and rights of participants are being protected; and that the study is being 
conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP guidelines, and all applicable regulatory requirements.  
10.1.9.  Study  and Site  Start and Closure  
The study  start date is the date on which  the clinical  study  will be open  for recruitment  of 
participants.  
The first act of recruitment  is the date of the first participant’s  first visit and will be the study 
start date.  
The sponsor  designee  reserves  the right  to close  the study  site or terminate  the study  at any 
time for any reason at the sole discretion of the sponsor, including (but not limited to) 
regulatory authority decision, change in opinion of the IRB/EC, or change in benefit -risk 
assessment. Study sites will be closed upon study completion. A study site is considered  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  73  
 closed  when  all required  documents  and study  supplies  have  been  collected  and a study -site 
closure visit has been performed.  
The investigator  may initiate  study -site closure  at any time upon  notification  to the sponsor 
or designee/CRO if requested to do so by  the responsible IRB/EC or if such termination is 
required to protect the health of study participants.  
Reasons  for the early  closure  of a study  site by the sponsor  may include  but are not limited 
to: 
• Failure  of the investigator  to comply  with the protocol,  the requirements  of the 
IRB/EC or local health authorities, the sponsor’s procedures, or the ICH GCP 
guidelines;  
• Inadequate  recruitment  of participants by  the investigator;  
• Discontinuation of further study  intervention development.  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators,  the ECs/IRBs,  the regulatory  authorities,  and any CRO(s)  used in the study  of 
the reason for termination or suspension, as specified by the applicable regulatory 
requirements. The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow -up. 
Study  termination  is also provided  for in the clinical  study  agreement.  If there  is any conflict 
between the contract and this protocol, the contract will control as to termination rights.  
10.1.10.  Publication  Policy  
For multicenter trials, the primary publication will be a joint publication developed by the 
investigator  and Pfizer  reporting  the primary  endpoint(s)  of the study  covering  all study  sites. 
The investigator agrees to refer to the primary publication in any subsequent publications.  
Pfizer  will not provide any  financial compensation  for the investigator’s participation in the 
preparation  of the primary  congress  abstract,  poster,  presentation,  or primary  manuscript  for 
the study.  
Investigators are free to publish individual center results that they deem to be clinically 
meaningful after publication of the overall results of the study or 12 months after primary 
completion  date or study  completion  at all sites,  whichever  occurs  first, subject  to the other 
requirements described in this section.  
The investigator will provide Pfizer an opportunity to review any proposed publication or  
any other type of disclosure of the study results (collectively, “publication”) before it is 
submitted or otherwise disclosed and will submit all publications to Pfizer 30 days before 
submission. If any patent action is required to protect intellectual property rights, the 
investigator agrees to delay the disclosure for a period not to exceed an additional 60 days 
upon  request  from  Pfizer.  This allows  Pfizer  to protect  proprietary  information  and to provide  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  74  
 comments, and the investigator will, on request, remove any previously undisclosed 
confidential  information  before  disclosure,  except  for any study -intervention  or Pfizer -related 
information necessary for the appropriate scientific presentation or understanding of the  
study results. For joint publications, should there be disagreement regarding interpretation 
and/or presentation of specific analysis results, resolution of, and responsibility for, such 
disagreements will be the collective responsibility of all authors of the publication.  
For all publications relating to the study, the investigator and Pfizer will comply with 
recognized ethical standards concerning publications and authorship, including those 
established by the International Committee of Medical Journal Editors. The investigator will 
disclose  any relationship  with Pfizer  and any relevant  potential  conflicts  of interest,  including 
any financial or personal relationship with Pfizer, in any publications. All authors will have 
access to the relevant statistical tables, figures, and reports (in their original format) required 
to develop the publication.  
10.1.11.  Sponsor’s  Medically  Qualified  Individual  
The contact information for the sponsor’s MQI for the study is documented in the study 
contact  list located  in the supporting  study  documentation/study  portal  or other  electronic 
system.  
To facilitate access to their investigator and the sponsor’s MQI for study -related medical 
questions  or problems  from  nonstudy  healthcare  professionals,  participants  are provided  with 
an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol and 
study intervention identifiers, (b) participant’s study identification number, (c) site 
emergency phone number active 24 hours/day, 7 days per week, and (d) Pfizer Call Center 
number.  
The ECC is intended to augment, not replace, the established communication pathways 
between  the participant  and their investigator and site  staff,  and between  the investigator  and 
sponsor study team. The ECC is only  to be used by healthcare professionals not involved in 
the research  study,  as a means  of reaching  the investigator  or site staff related  to the care of a 
participant. The Pfizer Call Center number is to be used when the investigator and site staff 
are unavailable. The Pfizer Call Center number is not for use by  the participant directly; if a 
participant calls that number directly, they will be directed back to the investigator site.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  75  
 10.2. Appendix  2: Clinical  Laboratory  Tests  
The following  safety  laboratory  tests will be performed  at times  defined  in the SoA section  of 
this protocol. Additional laboratory results may be reported on these samples as a result of  
the method of analysis or the type of analyzer used by the clinical laboratory, or as derived 
from calculated values. These additional tests would not require additional collection of 
blood.  Unscheduled  clinical  laboratory  measurements  may be obtained  at any time during  the 
study to assess any perceived safety issues.  
Table  5. Protocol -Required  Safety  Laboratory  Assessments  
 
Hematology  Chemistry  Urinalysis  Other  
Hemoglobin 
Hematocrit 
RBC count 
MCV  
MCH 
MCHC  
Platelet count 
WBC count 
Total  neutrophils 
(Abs)  
Eosinophils (Abs) 
Monocytes (Abs) 
Basophils (Abs) 
Lymphocytes  (Abs)  
Coagulation  
aPTT,PT,INR  
PT control  BUN  
Creatinine (Scr) 
Cystatin  C (Scys) 
eGFRa 
Plasma  Glucose 
(fasting) 
Calcium  
Sodium 
Potassium 
Chloride  
Total  CO 2 (Bicarbonate) 
AST 
ALT 
Alkaline  phosphatase 
GGT  
T bili 
Direct bilirubinb,c 
Indirect  bilirubinb,c 
Creatine kinaseb,d 
Uric acid  
Albumin 
Total  protein  pH 
Glucose  (qual) 
Protein (qual) 
Blood (qual) 
Ketones 
Nitrites 
Leukocyte 
esterase 
Urobilinogen 
Urine  bilirubin  
Microscopye Other  tests as part of clinical  laboratory  tests: 
At times specified in  SoA: 
• Urine pregnancy test (WOCBP only)f 
At screening  only:  
• Serology:  HBsAg,  HCVAb  (if positive,  HCV 
RNA) and HIV  
• Serum  FSH (all females)  
• Serum  pregnancy  test (β-hCG)  (all females)  
• Reticulocyte count (Abs)  
• Total bile acids  
• Amylase  
• Lipase  
At screening  and Day  -1 only: 
• Breath alcohol testg 
• Urine drug testh 
For suspected  DILI : 
• AST,  ALT 
• T bili, direct and indirect bilirubin  
• Total  bile acids,  GGT  
• Albumin  
• Alkaline  phosphatase  
• CK 
• PT, INR 
• Acetaminophen/paracetamol  or 
protein adduct levels  
   For suspected  DICI/DIKI:  
Creatinine (Scr)  
Cystatin  C (Scys) 
eGFRa  
Spot (dipstick)  UACR  
a. eGFR  should  be calculated  using  the 2021 CKD -EPI Scr-Scys  combined  equations,  see Appendix 7. 
b. At screening  and Day 1 only,  unless  conditions  for testing  are met after Day 1 per notes  “c” and “d” below.  
c. After  Day 1, direct  and indirect  bilirubin assessed  only when  T bili is > ULN.  
d. After  Day 1, creatine  kinase  assessed  only when  ALT  is > ULN.  
e. Only  if urine  dipstick  is positive  for blood,  protein,  nitrites  or leukocyte  esterase.  
f. Performed  on-site using  kits approved  by sponsor.  
g. Performed  on-site using  kits approved  by sponsor.  
h. Minimum  testing requirements  include cocaine,  THC, opiates and  opioids,  benzodiazepines and  amphetamines.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  76  
 The investigator  must  review  the laboratory  report,  document  this review,  and record  any 
clinically relevant changes occurring during the study in the AE section of the CRF.  
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may  be retained and 
stored for the duration of the study. Upon completion of the study, these retained safety 
samples  may be used for the assessment  of exploratory  safety  biomarkers  or unexpected 
safety findings. These data will not be included in the CSR. Samples to be used for this 
purpose will be shipped to either a Pfizer approved BBS facility or other designated 
laboratory and retained for up to 1 year following the completion of the study.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  77  
 10.3. Appendix  3: Adverse  Events:  Definitions  and Procedures  for Recording, 
Evaluating, Follow -Up, and Reporting  
10.3.1.  Definition of AE 
 
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study 
participant,  temporally  associated  with the use of study  intervention,  whether  or not 
considered related to the study intervention.  
• Note:  An AE can therefore  be any unfavorable  and unintended  sign (including  an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of study intervention.  
 
 
Events  Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or 
urinalysis) or other safety assessments (eg, ECG, radiological scans, vital sign 
measurements),  including  those  that worsen  from  baseline,  considered  clinically 
significant in the medical and scientific judgment of the investigator. Any 
abnormal laboratory test results that meet any of the conditions below must be 
recorded as an AE:  
• Is associated  with accompanying  symptoms;  
• Requires  additional  diagnostic  testing  or medical/surgical  intervention;  
• Leads  to a change  in study  dosing  (outside  of any protocol -specified  dose 
adjustments) or discontinuation from the study, significant additional 
concomitant drug treatment, or other therapy.  
• Exacerbation  of a chronic  or intermittent  preexisting  condition,  including  an 
increase in either frequency and/or intensity of the condition.  
• New  condition  detected  or diagnosed  after study  intervention  administration,  even 
though it may have been present before the start of the study.  
• Signs,  symptoms,  or the clinical  sequelae  of a suspected  drug-drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention  or a concomitant  medication.  Overdose  per se will not be reported  as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self -harming intent. Such overdoses should be reported regardless of 
sequelae.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  78  
  
 
Events  NOT  Meeting  the AE Definition  
• Any clinically  significant abnormal laboratory  findings or other abnormal safety 
assessments  that are associated  with the underlying  disease,  unless  judged  by the 
investigator to be more severe than expected for the participant’s condition.  
• The disease/disorder  being  studied  or expected  progression,  signs,  or symptoms  of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.  
• Medical  or surgical  procedure  (eg, endoscopy,  appendectomy):  the condition  that 
leads to the procedure is the AE.  
• Situations  in which  an untoward  medical  occurrence  did not occur  (social  and/or 
convenience admission to a hospital).  
• Anticipated  day-to-day fluctuations  of preexisting  disease(s)  or condition(s)  present 
or detected at the start of the study that do not worsen.  
10.3.2.  Definition of an  SAE  
 
An SAE  is defined  as any untoward  medical  occurrence  that,  at any dose,  meets  one 
or more of the criteria listed below:  
a.  Results in  death  
b. Is life -threatening  
The term “life-threatening”  in the definition  of “serious”  refers  to an event  in which  the 
participant  was at risk of death  at the time of the event.  It does not refer  to an event  that 
hypothetically might have caused death if it were more severe.  
c.  Requires  inpatient hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the participant has been admitted (usually 
involving  at least an overnight  stay)  at the hospital  or emergency  ward  for observation 
and/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious.  When in doubt as  to whether “hospitalization” occurred or was necessary,  the 
AE should be considered serious.  
Hospitalization  for elective  treatment  of a preexisting  condition  that did not worsen 
from baseline is not considered an AE.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  79  
  
d. Results  in persistent  or significant disability/incapacity  
• The term disability  means  a substantial  disruption  of a person’s  ability  to conduct 
normal life functions.  
• This definition  is not intended  to include  experiences  of relatively  minor  medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), that may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e.  Is a congenital  anomaly/birth  defect  
f. Is a suspected  transmission  via a Pfizer  product  of an infectious  agent,  pathogenic 
or non -pathogenic  
The event  may be suspected  from  clinical  symptoms  or laboratory  findings  indicating 
an infection in a participant exposed to a Pfizer product. The terms “suspected 
transmission” and “transmission” are considered synonymous. These cases are 
considered unexpected and handled as serious expedited cases by pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.  
g. Other situations:  
• Medical  or scientific  judgment  should  be exercised  by the investigator  in deciding 
whether SAE reporting is appropriate in other situations, such as significant 
medical events that may jeopardize the participant or may require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually be considered serious.  
• Examples  of such events  include  invasive  or malignant  cancers,  intensive  treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug 
dependency or drug abuse.  
10.3.3.  Recording/Reporting  and Follow -Up of AEs and/or  SAEs  During  the Active 
Collection Period  
 
AE and SAE Recording/Reporting  
The table  below  summarizes  the requirements  for recording  AEs on the CRF  and for 
reporting SAEs on the CT SAE Report Form to Pfizer Safety throughout the active 
collection  period.  These  requirements  are delineated  for 3 types  of events:  (1) SAEs;  
(2) nonserious  AEs;  and (3) exposure  to the study  intervention  under  study  during 
pregnancy or breastfeeding, and occupational exposure.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  80  
  
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same  as the AE page  of the CRF.  When  the same  data are collected,  the forms  must  be 
completed in a consistent manner. AEs should be recorded using concise medical 
terminology and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* EDP (with or without an associated AE or SAE): any pregnancy information is reported to Pfizer 
Safety  using  the CT SAE  Report  Form  and EDP  Supplemental  Form;  if the EDP  is associated  with 
an SAE, then the SAE is reported to Pfizer Safety using the CT SAE Report Form.  
** EDB  is reported  to Pfizer  Safety  using  the CT SAE  Report  Form, which  would  also include  details 
of any SAE that might be associated with the EDB.  
*** Environmental  or occupational  exposure:  AEs or SAEs  associated  with occupational  exposure 
are reported to Pfizer Safety using the CT SAE Report Form.  
 
• When  an AE or SAE  occurs,  it is the responsibility  of the investigator  to review  all 
documentation (eg, hospital progress notes, laboratory reports, and diagnostic 
reports) related to the event.  
• The investigator  will then record  all relevant  AE or SAE  information  in the CRF.  Safety Event  Recorded  on the CRF  Reported on the CT SAE 
Report Form to Pfizer 
Safety  Within  24 Hours  of 
Awareness  
SAE All All 
Nonserious  AE All None  
Exposure to the study 
intervention  under  study 
during pregnancy or 
breastfeeding  All AEs/SAEs  associated 
with EDP or EDB  
 
Note: Instances of EDP or 
EDB  not associated  with an 
AE or SAE  are not captured 
in the CRF  All instances  of EDP  are 
reported  (whether  or not 
there is an associated 
SAE)*  
All instances  of EDB  are 
reported (whether or not 
there is an associated 
SAE)**  
Environmental or 
occupational  exposure  to 
the product under study 
to a nonparticipant (not 
involving EDP or EDB)  None.  Exposure  to a study 
non-participant is not 
collected on the CRF  The exposure  (whether  or 
not there is an associated 
AE or SAE) must be 
reported***  
 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  81  
  
• It is not acceptable  for the investigator  to send photocopies  of the participant’s 
medical records to Pfizer Safety in lieu of completion of the CT SAE Report 
Form/AE or SAE CRF page.  
• There may be instances when copies of medical records for certain cases are 
requested by Pfizer Safety. In this case, all participant identifiers, with the 
exception  of the participant  number,  will be redacted  on the copies  of the medical 
records before submission to Pfizer Safety.  
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms,  and/or  other  clinical  information.  Whenever  possible,  the diagnosis  (not 
the individual signs/symptoms) will be documented as the AE or SAE.  
Assessment of Intensity  
The investigator  will make  an assessment  of intensity  for each AE and SAE  reported 
during the study and assign it to 1 of the following categories:  
• Mild: A type of AE that is usually transient and may require only minimal 
treatment  or therapeutic  intervention.  The event  does not generally  interfere  with 
usual ADL.  
• Moderate: A type of AE that is usually alleviated with additional specific 
therapeutic  intervention.  The event  interferes  with usual  ADL,  causing  discomfort, 
but poses no significant or permanent risk of harm to the research participant.  
• Severe:  A type of AE that interrupts  usual  ADL,  or significantly  affects  clinical 
status, or may require intensive therapeutic intervention.  
An event  is defined  as “serious”  when  it meets  at least 1 of the predefined  outcomes  as 
described in the definition of an SAE, NOT when it is rated as severe.  
 
 
Assessment of Causality  
• The investigator  is obligated  to assess  the relationship  between  study  intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or  arguments  to suggest  a causal  relationship,  rather  than a relationship  cannot 
be ruled out.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  82  
  
• Alternative  causes,  such as underlying  disease(s),  concomitant therapy,  and other 
risk factors,  as well as the temporal  relationship  of the event  to study  intervention 
administration, will be considered and investigated.  
• The investigator  will also consult  the IB and/or  product  information,  for marketed 
products, in their assessment.  
• For each AE or SAE,  the investigator must  document  in the medical  notes  that they 
have reviewed the AE or SAE and have provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every  event  before  the initial  transmission  of the SAE  data  to the sponsor . 
• The investigator  may change  their opinion  of causality  in light of -follow -up 
information and send an SAE -follow -up report with the updated causality 
assessment.  
• The causality  assessment  is one of the criteria  used when  determining  regulatory 
reporting requirements.  
• If the investigator does not know whether or not the study intervention caused the 
event,  then the event  will be handled  as “related  to study  intervention”  for reporting 
purposes, as defined by the sponsor. In addition, if the investigator determines that 
an SAE is associated with study procedures, the investigator must record this  
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.  
 
 
Follow -Up of AEs and SAEs  
• The investigator  is obligated  to perform  or arrange  for the conduct  of supplemental 
measurements and/or evaluations, as medically indicated or as requested by the 
sponsor, to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other healthcare providers.  
• If a participant dies during participation in the study or during a recognized 
follow -up period,  the investigator  will provide  Pfizer  Safety  with a copy  of any 
postmortem findings, including histopathology.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  83  
  
• New  or updated  information  will be recorded  in the originally  submitted 
documents.  
• The investigator  will submit  any updated  SAE  data to the sponsor  within  24 hours 
of receipt of the information.  
10.3.4.  Reporting of SAEs  
 
SAE  Reporting  to Pfizer  Safety  via an Electronic  DCT  
• The primary  mechanism  for reporting  an SAE  to Pfizer  Safety  will be the 
electronic DCT.  
• If the electronic  system  is unavailable,  then the site will use the paper  SAE  DCT 
(see next section) to report the event within 24 hours.  
• The site will enter  the SAE  data into the electronic  DCT  (eg, eSAE  or PSSA)  or 
paper form (as applicable) as soon as the data become available.  
• After  the study  is completed  at a given  site, the electronic  DCT  will be taken 
off-line to prevent the entry of new data or changes to existing data.  
• If a site receives  a report  of a new SAE  from  a study  participant  or receives  updated 
data on a previously  reported  SAE  after the electronic  DCT  has been  taken  off-line, 
then the site can report this information on a paper SAE form (see next section) or 
to Pfizer Safety by telephone.  
 
 
SAE  Reporting  to Pfizer  Safety  via the CT SAE  Report  Form  
• Facsimile  transmission  of the CT SAE  Report  Form  is the preferred  method  to 
transmit this information to Pfizer Safety.  
• In circumstances  when  the facsimile  is not working,  an alternative  method  should 
be used, eg, secured (Transport Layer Security) or password -protected email. If 
none of  these methods  can be used,  notification by telephone is acceptable with a 
copy of the CT SAE Report Form sent by overnight mail or courier service.  
• Initial notification via telephone does not replace the need for the investigator to 
complete  and sign the CT SAE  Report  Form  pages  within  the designated  reporting 
time frames.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  84  
 10.4. Appendix  4: Contraceptive  and Barrier  Guidance  
10.4.1.  Male  Participant  Reproductive  Inclusion  Criteria  
No contraception methods are required for male participants in this study, as the calculated 
safety  margin  is ≥100 -fold between  the estimated  maternal  exposure  due to seminal  transfer 
and the NOAEL  for serious  manifestations  of developmental  toxicity  in nonclinical  studies.  
10.4.2.  Female  Participant  Reproductive  Inclusion  Criteria  
The criteria below are part of Inclusion Criterion 1 (Age and Sex; Section 5.1 ) and specify 
the reproductive  requirements  for including  female  participants.  Refer  to Section  10.4.4  for a 
complete list of contraceptive methods permitted in the study.  
A female participant  is eligible  to participate  if she (a) is not pregnant  or breastfeeding; and 
(b) agrees  not to donate  eggs (ova,  oocytes)  for the purpose  of reproduction  for 28 days after 
last dose of study intervention; and (c) at least 1 of the following conditions applies:  
• Is not a WOCBP  (see definition  in Section  10.4.3 ). 
OR 
• Is a WOCBP  and agrees  to use a contraceptive  method  that is highly  effective  (failure 
rate of <1% per year) with low user dependency  during the intervention period and 
agrees to use it for at least 28 days after the last dose of study intervention, which 
corresponds to the time needed to eliminate any reproductive safety risk of the study 
intervention(s). The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study intervention.  
OR 
• Is a WOCBP and agrees to use a highly effective (failure rate of <1% per year) 
user-dependent  method  of contraception  during  the intervention  period  and for at 
least 28 days after the last dose of study  intervention, which corresponds to the time 
needed to eliminate any reproductive safety risk of the study intervention(s). In 
addition to her use of the highly effective method above, she agrees to concurrently  
use an effective  barrier  method.  The investigator  should  evaluate  the effectiveness  of 
the contraceptive method in relationship to the first dose of study intervention.  
The investigator  is responsible  for review  of medical  history,  menstrual  history,  and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetected 
pregnancy.  
10.4.3.  Woman  of Childbearing  Potential  
A woman  is considered  fertile  following  menarche  and until becoming  postmenopausal 
unless permanently sterile (see below).  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  85  
 If fertility  is unclear  (eg, amenorrhea  in adolescents  or athletes)  and a menstrual  cycle  cannot 
be confirmed before the first dose of study intervention, additional evaluation should be 
considered.  
Women  in the following  categories  are not considered  WOCBP:  
1. Premenopausal  female  with 1 of the following:  
• Documented  hysterectomy;  
• Documented bilateral salpingectomy;  
• Documented  bilateral  oophorectomy.  
For individuals with permanent infertility due to a medical cause other than the above 
(eg, mullerian  agenesis,  androgen  insensitivity),  investigator  discretion  should  be applied 
to determining study entry.  
Note:  Documentation  for any of the above  categories  can come  from  the site personnel’s 
review of the participant’s medical records, medical examination, or medical history 
interview.  The method  of documentation  should  be recorded  in the participant’s  medical 
record for the study.  
2. Postmenopausal  female.  
• A postmenopausal  state is defined  as no menses  for 12 months  without  an 
alternative medical cause. In addition:  
• A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal  state in women  under  60 years  old and not using  hormonal 
contraception or HRT.  
• A female  on HRT  and whose  menopausal  status  is in doubt  will be required  to 
use one of the highly effective nonestrogen hormonal contraception methods 
if she wishes to continue her HRT during the study. Otherwise, she must 
discontinue  HRT  to allow  confirmation  of postmenopausal  status  before  study 
enrollment.  
10.4.4.  Contraception  Methods  
Contraceptive  use by men or women  should  be consistent  with local  availability/regulations 
regarding the use of contraceptive methods for those participating in clinical trials.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  86  
 The following  contraceptive  methods  are appropriate  for this study: 
Highly Effective Methods  That Have Low User Dependency  
1. Implantable  progestogen -only hormone  contraception  associated  with inhibition  of 
ovulation.  
2. Intrauterine  device.  
3. Intrauterine  hormone -releasing  system.  
4. Bilateral  tubal  occlusion.  
5. Vasectomized  partner.  
• Vasectomized  partner  is a highly  effective  contraceptive  method  provided  that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed.  If not, an additional highly effective method of contraception 
should be used.  The spermatogenesis cycle is approximately 90 days.  
Highly  Effective  Methods  That Are User  Dependent  
6. Combined  (estrogen - and progestogen -containing)  hormonal  contraception  associated 
with inhibition of ovulation:  
• Oral + barrier*;  
• Intravaginal  + barrier*;  
• Transdermal  + barrier*.  
7. Progestogen -only hormone  contraception  associated  with inhibition  of ovulation:  
• Oral + barrier*;  
• Injectable  + barrier*.  
8. Sexual Abstinence  
Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.  The reliability  of sexual  abstinence  needs  to be evaluated 
in relation to the duration of the study and the preferred and usual lifestyle of the 
participant.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  87  
 * Acceptable  barrier  methods  to be used concomitantly  with options  6 or 7 for  the study 
include any of the following:  
• Male  or female  condom  with or without  spermicide;  
• Cervical  cap, diaphragm,  or sponge  with spermicide;  
• A combination  of male  condom  with either  cervical  cap, diaphragm,  or sponge  with 
spermicide (double -barrier methods).  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  88  
  
 
 
 
 
 
 
 
 
 
 
 
 CCI 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  89  
 10.6. Appendix  6: Liver  Safety:  Suggested  Actions  and Follow -Up Assessments 
Potential Cases of Drug -Induced Liver Injury  
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases)  are termed  “tolerators,”  while  those  who show  transient  liver injury  but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
“susceptible” to progressive and serious liver injury, commonly referred to as DILI. 
Participants who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently to determine if they are “adaptors” or are “susceptible.”  
In the majority  of DILI  cases,  elevations  in AST  and/or  ALT  precede  T bili elevations 
(>2 × ULN) by several days or weeks. The increase in T bili typically occurs while 
AST/ALT is/are still elevated above 3 × ULN (ie, AST/ALT and T bili values will be  
elevated  within  the same  laboratory  sample).  In rare instances,  by the time T bili elevations 
are detected, AST/ALT values might have decreased. This occurrence is still regarded as a 
potential DILI.  Therefore,  abnormal elevations in either AST OR ALT in addition to T bili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law 
criteria) cases and should always be considered important medical events, even before all 
other possible causes of liver injury have been excluded.  
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s  individual  baseline  values  and underlying  conditions.  Participants  who present 
with the following laboratory abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:  
• Participants  with AST/ALT  and T bili baseline  values  within  the normal  range  who 
subsequently present with AST OR ALT values ≥3 × ULN AND a T bili value  
≥2 × ULN  with no evidence  of hemolysis  and an alkaline  phosphatase  value  
<2 × ULN or not available.  
• For participants  with baseline  AST  OR ALT  OR T bili values  above  the ULN,  the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:  
• Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values  ≥2 times  the baseline  values  AND  ≥3 × ULN;  or ≥8 × ULN  (whichever  is 
smaller).  
• Preexisting  values  of T bili above  the normal  range:  T bili level  increased  from 
baseline value by an amount of ≥1 × ULN or if the value reaches ≥3 × ULN 
(whichever is smaller).  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  90  
 Rises in AST/ALT and T bili separated by more than a few weeks should be assessed 
individually  based  on clinical  judgment;  any case where  uncertainty  remains  as to whether  it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, 
preferably  within  48 hours  from  awareness  of the abnormal  results.  This evaluation  should 
include laboratory tests, detailed history, and physical assessment.  
In addition to repeating measurements of AST and ALT and T bili for suspected Hy’s law 
cases, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analyses at the time of the recognized initial 
abnormalities to determine etiology. A detailed history, including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by itself or as a coformulated 
product in prescription or over -the-counter medications), recreational drug, or supplement 
(herbal)  use and consumption,  family  history,  sexual  history,  travel  history,  history  of contact 
with a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis  A, B, C, D, and E infection,  liver imaging  (eg, biliary  tract),  and collection  of serum 
samples for acetaminophen/paracetamol drug and/or protein adduct levels may  be warranted.  
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/ALT and 
T bili elevation defined above should be considered potential DILI (Hy’s law) cases if no 
other  reason  for the LFT abnormalities  has yet  been  found.  Such  potential  DILI  (Hy’s  law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.  
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable  investigations  have  been  received  and have  excluded  an alternative  etiology.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  91  
 10.7. Appendix  7: Kidney  Safety:  Monitoring  Guidelines  
10.7.1.  Laboratory  Assessment  of Change  in Kidney  Function  and Detection  of Kidney 
Injury  
Standard kidney safety monitoring requires assessment of baseline and postbaseline serum 
creatinine. Additionally, baseline and postbaseline serum Scys makes it feasible to 
distinguish AKI from other causes of Scr increase.  In this study, eGFR will be determined 
using  the 2021  CKD -EPI Scr-Scys  combined  equation  (see Section  10.7.2.1  below)  and both 
Scr and Scys will be measured  as part of  the protocol -required  safety  laboratory  assessments 
at all times specified in the SoA. 
Regardless of whether kidney function monitoring tests are required as a routine safety 
monitoring  procedure  in the study,  if the investigator  or sponsor  deems  it necessary  to further 
assess kidney safety and quantify kidney function, then these test results should be managed 
and followed per standard of care.  
10.7.2.  Age-Specific  Kidney  Function  Calculation  Recommendations  
10.7.2.1.  Adults  (18 Years  and Above) —2021  CKD -EPI Equations13 
 
2021  CKD -EPI 
Scr-Scys 
Combined  Scr 
(mg/dL)  Scys 
(mg/L)  Recommended  eGFR  Equation  
Female  if ≤0.7 if ≤0.8 eGFR  = 130 × (Scr/0.7)-0.219  × (Scys/0.8)-0.323  × (0.9961)Age 
Female  if ≤0.7 if >0.8 eGFR  = 130 × (Scr/0.7)-0.219  × (Scys/0.8)-0.778  × (0.9961)Age 
Female  if >0.7 if ≤0.8 eGFR  = 130 × (Scr/0.7)-0.544  × (Scys/0.8)-0.323  × (0.9961)Age 
Female  if >0.7 if >0.8 eGFR  = 130 × (Scr/0.7)-0.544  × (Scys/0.8)-0.778  × (0.9961)Age 
Male  if ≤0.9 if ≤0.8 eGFR  = 135 × (Scr/0.9)-0.144  × (Scys/0.8)-0.323  × (0.9961)Age 
Male  if ≤0.9 if >0.8 eGFR  = 135 × (Scr/0.9)-0.144  × (Scys/0.8)-0.778  × (0.9961)Age 
Male  if >0.9 if ≤0.8 eGFR  = 135 × (Scr/0.9)-0.544  × (Scys/0.8)-0.323  × (0.9961)Age 
Male  if >0.9 if >0.8 eGFR  = 135 × (Scr/0.9)-0.544  × (Scys/0.8)-0.778  × (0.9961)Age 
10.7.3.  Adverse  Event  Grading  for Kidney  Safety  Laboratory  Abnormalities  
AE grading  for decline  in kidney  function  (ie, eGFR  or eCrCl)  will be according  to KDIGO 
criteria.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  92  
 10.8. Appendix  8: ECG  Findings  of Potential  Clinical  Concern  
 
ECG  Findings That  May  Qualify  as AEs 
• Marked  sinus  bradycardia  (rate <40 bpm)  lasting  minutes.  
• New  PR interval  prolongation >280 ms. 
• New prolongation of QTcF to >480 ms (absolute) or by  ≥60 ms from baseline.  
• New -onset  atrial  flutter  or fibrillation,  with controlled  ventricular  response  rate: 
ie, rate <120 bpm.  
• New -onset  type I second -degree  (Wenckebach)  AV block  of >30 seconds’ 
duration.  
• Frequent  PVCs,  triplets,  or short  intervals  (<30  seconds)  of consecutive  ventricular 
complexes.  
ECG  Findings That  May  Qualify  as SAEs  
• QTcF prolongation >500 ms. 
• New  ST-T changes  suggestive  of myocardial  ischemia.  
• New -onset  LBBB  (QRS  complex>120  ms). 
• New -onset  right  bundle  branch  block  (QRS  complex>120  ms). 
• Symptomatic  bradycardia.  
• Asystole:  
• In awake,  symptom -free participants  in sinus  rhythm,  with documented  periods 
of asystole  ≥3.0 seconds  or any escape  rate <40 bpm,  or with an escape  rhythm 
that is below the AV node.  
• In awake,  symptom -free participants  with atrial  fibrillation  and bradycardia 
with 1 or more pauses of at least 5 seconds or longer.  
• Atrial  flutter  or fibrillation,  with rapid  ventricular  response  rate: rapid  = rate 
>120  bpm.  
• Sustained  supraventricular  tachycardia  (rate >120  bpm)  (“sustained”  = short 
duration with relevant symptoms or lasting >1 minute).  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  93  
  
• Ventricular  rhythms  >30 seconds’  duration,  including  idioventricular  rhythm  (HR 
<40 bpm),  accelerated  idioventricular  rhythm  (HR >40 bpm to <100  bpm),  and 
monomorphic/polymorphic ventricular tachycardia (HR >100 bpm [such as 
torsades de pointes]).  
• Type II  second -degree  (Mobitz II)  AV block.  
• Complete  (third -degree)  heart  block.  
ECG  Findings That  Qualify as  SAEs  
• Change  in pattern  suggestive  of new myocardial  infarction.  
• Sustained  ventricular  tachyarrhythmias  (>30  seconds’  duration).  
• Second - or third -degree  AV block  requiring  pacemaker  placement.  
• Asystolic  pauses  requiring  pacemaker  placement.  
• Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.  
• Ventricular  fibrillation/flutter.  
• At the discretion  of the investigator,  any arrhythmia  classified  as an adverse 
experience.  
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications  from  the core ECG  laboratory  to the investigator  and Pfizer  study  team,  and not to be 
considered as all -inclusive of what to be reported as AEs/SAEs.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  94  
 CCI  
 
 
 
 
 
 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  95  
  
 CCI 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  96  
  
 
CCI 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  97  
 10.10.  Appendix  10: Other  Prohibited  Prior/Concomitant  Medications  
The following  medications  are prohibited  until the follow -up contact,  unless  stated  otherwise. 
If a participant receives a prohibited medication, the investigator should contact the sponsor 
clinician or sponsor medical monitor to determine if the participant should be included in the 
study/continued in the study.  
 
Drug  Classes  and/or  Drugs  Timeframe  of Restriction  
Other  GLP -1R agonists  90 days prior  to screening  visit until final follow 
up contact  
DPP-4 inhibitors,  pramlintide,  repaglinide  Screening  visit until final follow -up contact  
Systemic glucocorticoids such as prednisone, 
dexamethasone, triamcinolone, budesonide, 
betamethasone. Note:  As an exception, steroid - 
containing  inhalers,  nasal  sprays  and topical  formulations 
are permitted.  Screening  visit until final follow -up contact  
Immunosuppressants  such as cyclosporine  and 
tacrolimus.  Screening  visit until final follow -up contact  
Cannabinoids  (eg, medically  prescribed  THC)  Screening  visit until final follow -up contact  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  98  
 10.11.  Appendix  11: Child -Pugh  Classification  (CPC)  of Liver  Dysfunction 
Table 6.  Scoring for Child -Pugh Classification14 
Group   CPC  Level of 
dysfunction  Total  Score  
(tally  based  on assessment  of 
parameters in Table 7 ) 
1  Not Applicable  Without  hepatic 
impairment  Not Applicable  
2  A Mild 5-6 
3  B Moderate  7-9 
4  C Severe  ≥10 
Table  7. Derivation  of Child -Pugh  Classification  Score  
 
Assessment  Parameters  Assigned  score  for observed  findings  
1 point  2 points  3 points  
Encephalopathy gradea 
(refer  to Table  8 below)  0 1 or 2 3 or 4a 
Ascites  Absent  Asymptomatic  Requiring  intervention  
Serum  T bili, mg/dL  <2 2 to 3 >3 
Serum  albumin,  g/dL >3.5 2.8 to 3.5 <2.8 
PT, sec prolonged  <4 4 to 6 >6 
a. Participants  with a prior  history  of Grade  3 or 4 encephalopathy  who are currently  receiving  
an intervention [ eg, lactulose or lactitol, alone or in combination with rifaximin, and/or neomycin] to 
manage encephalopathy  related signs and symptoms should be scored for encephalopathy grading based  
on their  presentation  while  on intervention  at the screening  visit and can be included  in Study  C3991009 
as long as they do not have clinically active Grade 3 or 4 encephalopathy.  
 
Table  8. Determination  of Encephalopathy  Grade  
 
Encephalopathy  Grade  Definition  
0 Normal  consciousness,  personality,  neurological  exam  
1 Restless,  sleep  disturbed,  irritable/agitated,  tremor,  impaired  handwriting  
2 Lethargic,  time-disoriented,  inappropriate,  asterixis,  ataxia  
3a Somnolent,  stuporous,  place -disoriented,  hyperactive  reflexes,  rigidity  
4a Unrousable  coma,  no personality/behavior,  decerebrate  
a. Participants  with clinically  active  Grade  3 or 4 encephalopathy  are excluded.  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  99  
 10.12.  Appendix  12: Abbreviations  
The following is a list of abbreviations that may  be used in the protocol.  
 
Abbreviation  Term  
Abs absolute  
ADL  activity/activities  of daily  living  
AE adverse  event  
AKI acute kidney  injury  
ALT  alanine aminotransferase  
ANOVA  analysis  of variance  
aPTT  activated partial thromboplastin time 
AST aspartate aminotransferase  
AUC  area under  the concentration -time curve  
AUC 24 area under  the plasma  concentration -time profile  over 24 hours  
AUC inf area under  the plasma  concentration -time profile  from  time zero 
extrapolated to infinite time  
AUC inf,u unbound  area under  the plasma  concentration -time profile  from 
time zero extrapolated to infinite time  
AUC last area under  the plasma  concentration -time profile  from  time zero to 
the time of the last quantifiable concentration  
AUC last,u  unbound  area under  the plasma  concentration -time profile  from 
time zero to the time of the last quantifiable concentration  
AUC tau area under  the plasma  concentration -time profile  over tau, the 
dosing interval, where tau = 24 hours  
AV atrioventricular  
AxMP  auxiliary  medicinal product  
-hCG -human  chorionic  gonadotropin  
BBS Biospecimen  Banking  System  
BMI body  mass  index  
BP blood  pressure  
bpm beats  per minute  
BUN  blood  urea nitrogen  
cAMP  cyclic  adenosine  monophosphate  
CFR Code of Federal Regulations  
CI confidence  interval  
CIOMS  Council  for International  Organizations  of Medical  Sciences  
CK creatine  kinase  
CKD -EPI chronic kidney  disease epidemiology  
CL total clearance  of drug from  eg, plasma  
 CCI     
    
Clast last quantifiable concentration  
Cmax maximum  plasma  concentration  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  100  
  
Abbreviation  Term  
Cmax,u  unbound maximum plasma concentration  
CO 2 carbon  dioxide  (bicarbonate)  
COVID -19 coronavirus  disease  2019  
CPC Child -Pugh  Classification  
 CCI     
CRF case report  form 
CRO  contract research organization  
CRU  clinical  research  unit 
CSR Clinical Study  Report  
CT clinical  trial 
CTIS  Clinical  Trial  Information  System  
CT scan computed  tomography  scan 
CYP  cytochrome  P450  
DBP  diastolic  blood  pressure  
DCT  data collection  tool 
DDI drug-drug interaction  
DICI  drug-induced  creatinine  increase  
DIKI  drug-induced  kidney  injury  
DILI  drug-induced  liver injury  
 CCI     
DPP-4 dipeptidyl  peptidase -4 
EC ethics  committee  
ECC  emergency  contact  card 
ECG  electrocardiogram or electrocardiography  
eCrCl  estimated  creatinine  clearance  
eCRF  electronic case report form  
EDB  exposure during breastfeeding  
E-DMC  External Data Monitoring Committee  
EDP exposure  during  pregnancy  
EFD embryo -fetal development  
eGFR  estimated  glomerular  filtration  rate 
eSAE  electronic  serious  adverse  event  
EU European  Union  
EudraCT  European  Union  Drug  Regulating  Authorities  Clinical  Trials 
(European Clinical Trials Database)  
FIH first-in-human  
FSH follicle -stimulating  hormone  
fu fraction of unbound drug in plasma  
GCP  Good  Clinical  Practice  
GGT  gamma -glutamyl  transferase  
GLP-1 glucagon -like peptide -1 
GLP-1R glucagon -like peptide -1 receptor  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  101  
  
Abbreviation  Term  
H hour 
HAE  hypoglycemic  adverse  event  
HBsAg  hepatitis B surface antigen  
HCVAb  hepatitis C antibody  
HIV human  immunodeficiency  virus  
HR heart  rate 
HRT  hormone  replacement  therapy  
IB Investigator’s  Brochure  
ICD informed  consent  document  
ICH International  Council  for Harmonisation  of Technical 
Requirements for Pharmaceuticals for Human Use  
ID identification  
IMP investigational  medicinal  product  
IND Investigational  New  Drug  
INR international  normalized  ratio 
IPAL  Investigational Product Accountability  Log 
IPM investigational  product  manual  
IRB Institutional  Review  Board  
IV intravenous(ly)  
IVGTT  intravenous  glucose  tolerance  test 
K2EDTA  dipotassium  edetic  acid (ethylenediaminetetraacetic  acid)  
kel first-order  elimination  rate constant  
KDIGO  Kidney  Disease Improving Global Outcomes  
LBBB  left bundle  branch  block  
LFT liver function  test 
MCH  mean corpuscular hemoglobin  
MCHC  mean  corpuscular  hemoglobin  concentration  
MCV  mean corpuscular volume  
MEN2  multiple  endocrine  neoplasia  type 2 
MQI  medically  qualified individual  
MRI magnetic resonance imaging  
MTC  medullary  thyroid  carcinoma  
NA Not Applicable  
NIMP  noninvestigational  medicinal  product  
NOAEL  no observed  adverse  effect  level  
NRU  neutral  red uptake  
OATP  organic  anion  transporting  polypeptide  
PD pharmacodynamic(s)  
PE physical  examination  
PK pharmacokinetic(s)  
PO per os (by mouth)  
PPI proton pump inhibitor  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  102  
  
Abbreviation  Term  
PSSA  Pfizer's  Serious  Adverse  Event  Submission  Assistant  
PT prothrombin time 
PVC  premature  ventricular  contraction/complex  
QD once  daily  
QTc corrected  QT interval  
QTcF  QTc corrected  using  Fridericia’s  formula  
qual qualitative  
RBC  red blood  cell 
RNA  ribonucleic  acid 
SAE serious  adverse  event  
SAP Statistical  Analysis  Plan 
SARS -CoV-2 severe  acute  respiratory  syndrome  coronavirus  2 
SBP systolic  blood  pressure  
Scr serum creatinine  
Scys serum  cystatin  C 
SoA schedule  of activities  
SOC  System  Organ  Class  
SOP standard operating procedure  
SRSD  Single Reference Safety  Document  
SSID  single subject identifier  
SUSAR  Suspected  Unexpected  Serious  Adverse  Reaction  
t½ terminal  phase  half-life 
T2DM  Type  2 Diabetes  Mellitus  
T bili total bilirubin  
TEAE  treatment -emergent  adverse  event  
THC  tetrahydrocannabinol  
 CCI     
UACR  urine albumin/creatinine ratio 
UGT  uridine  5’-diphospho -glucuronosyltransferase  
ULN  upper  limit  of normal  
US United  States  
 CCI     
      
WBC  white  blood  cell 
WOCBP  woman/women  of childbearing  potential  
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  103  
 11. REFERENCES  
1. Orskov C, Holst JJ, Knuhtsen S, et al. Glucagon -like peptides GLP -1 and GLP -2, 
predicted  products  of the glucagon  gene,  are secreted  separately  from  pig small  intestine 
but not pancreas. Endocrinology. 1986;119(4):1467 -75. 
2. Kreymann  B, Williams  G, Ghatei  MA, et al. Glucagon -like peptide -1 7-36: a 
physiological incretin in man. Lancet. 1987;2(8571):1300 -4. 
3. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon -like peptide 1 inhibition of 
gastric  emptying  outweighs  its insulinotropic  effects  in healthy  humans.  Am J Physiol. 
1997;273(5):E981 -8. 
4. Flint  A, Raben  A, Astrup  A, et al. Glucagon -like peptide  1 promotes  satiety  and 
suppresses energy intake in humans. J Clin Invest. 1998;101(3):515 -20. 
5. US Food and Drug Administration. Guidance for industry: S10 Photosafety  evaluation 
of pharmaceuticals.  Rockville,  MD:  Center  for Biologics  Evaluation  and Research;  Jan 
2015.  
6. Nauck  MA, Quast  DR, Wefers  J, et al. GLP -1 receptor  agonists  in the treatment  of 
type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.  
7. Drucker  DL. The ascending  GLP -1 road from  clinical  safety  to reduction  of 
cardiovascular complications. Diabetes.2018;67:1710 -9. 
8. Lorenz  M, Lawson  F, Owens  D, et al. Differential  effects  of glucagon -like peptide -1 
receptor agonists on heart rate. Cardiovasc Diabetol.2017;16:6.  
9. Hachad H, Ragueneau -Majlessi I and Levy RH. A useful tool for drug interaction 
evaluation:  the University  of Washington  Metabolism  and Transport  Drug  Interaction 
Database. Hum Genomics. 2010;5(1):61 -72. 
10. Tan ML, Yoshida K, Zhao P, et al.  Effect of chronic kidney  disease on nonrenal 
elimination  pathways:  a systematic  assessment  of CYP1A2,  CYP2C8,  CYP2C9, 
CYP2C19, and OATP. Clin Pharmacol Ther. 2018; 103(5):854 -67. 
11. Banholzer ML, Wandel C, Barrow P, et al. Clinical trial considerations on male 
contraception  and collection  of pregnancy  information  from  female  partner:  update.Clin 
Transl Med 2016;5(1):23 -37. 
12. American  Diabetes  Association.  Standards  of medical  care in diabetes  -2019.  Diabetes 
Care 2019;42(Suppl 1):S1 -S193.  
13. Inker  LA, Eneanya  ND, Coresh  J, et al. New  Creatinine - and Cystatin  C-Based 
Equations to Estimate GFR without Race. N Engl J Med. 2021;385:1737 -49. 
PF-07081532  
Protocol  C3991009  
Final  Protocol,  18 May 2022  
PFIZER  CONFIDENTIAL  
Page  104  
 14. Pugh  RN, Murray -Lyon  IM, Dawson  JL, et al. Transection  of the oesophagus  for 
bleeding oesophageal varices. Br J Surg. 1973;60(8):646 -9. 